

Birth date: 06/03/1973
Nationality: Swiss
Marital status: married, two children
Mother language: French
English and German written and spoken

Professional address:
Département de chirurgie
Hôpitaux Universitaires de Genève
4, rue Gabrielle-Perret-Gentil
1205 Genève
Ph.: +41 (0)22 372 76 93
Fax: +41 (0)22 372 77 55
Cell: +41 (0)79 615 08 43
E-mail: christian.toso@hcuge.ch

Private address:
5, chemin Neuf-de-Vésenaz
1222 Vésenaz
Ph.: +41 (0)22 301 42 64

Current position

Jan 13- Assistant Professor-SNF Faculty of Medicine, Department of Surgery,
University of Geneva, Geneva, Switzerland
Jan. 11- Médecin Adjoint Agrégé Divisions of abdominal and transplant surgery,
Department of Surgery, University of Geneva
Hospitals, Geneva, Switzerland
Activity: research (40%), clinic (40%), teaching (10%), administration (10%)

Diplomas

Jan. 2010 Abdominal surgery advanced degree (FMH, Schwerpunkt)
Jan. 2009 European Health Leadership Program (INSEAD “The Business School of the
World”, Fontainebleau, France)
Dec. 2008 PhD (University of Alberta)
Thesis: “Monitoring and improving islet transplant outcomes”
Supervisor: Prof. James Shapiro, University of Alberta, Edmonton, Canada
Dec. 2007 American Society of Transplant Surgeons (ASTS) fellowship (University of
Alberta)
Nov. 2002 General surgery degree (FMH)
Nov. 1997 Diploma and Doctorate in Medicine (University of Geneva)
Thesis: “Isolation, preservation and transplantation of pig islet of Langerhans:
review and future perspectives”
Supervisor: Prof. Philippe Morel, University of Geneva, Switzerland

Courses:

Nov. 2017	Media Training course (Lausanne, Switzerland)
April 2011	Robotic Da Vinci hands-on one-day course (CMU-HUG)
Feb. 2011	Training in assessing and coaching collaborators (HUG)
Dec. 2002	AO course (Trauma, Swiss resident course, Davos, Switzerland)
May 2002	Hesperis Course (Transplantation, 2 week-course of the European Society of Transplantation, Geneva and Brussels)
May 2001	ATLS certification (Advanced Trauma Life Support, Geneva)
Sept. 1997	ECFMG certification -English test (Sept. 97) -clinical sciences examination (August 96) -basic medical sciences examination (Sept. 95)

Medical training and appointments

Nov. 09-Jan. 11	Médecin Adjoint	Divisions of abdominal and transplant surgery, Department of Surgery, University of Geneva Hospitals, Geneva, Switzerland
July 09-Oct. 09	Médecin Chef-de-Clinique	Divisions of abdominal and transplant surgery, Department of Surgery, University of Geneva Hospitals, Geneva, Switzerland
Dec. 08-June 09	Assistant Professor (clinical)	Hepato-pancreato-biliary and transplant surgery University of Alberta, Edmonton, Canada
Dec. 07-Dec. 08	Fellow, PhD student	Cell and Islet transplant laboratory (Prof. J. Shapiro, Alberta Diabetes Institute, University of Alberta, Edmonton, Canada)
Dec. 05-Dec. 07	Clinical Fellow, PhD student	Hepato-pancreato-biliary and transplant surgery (Prof. N. Kneteman, University of Alberta, Edmonton, Canada)
Oct. 05-Dec. 05	Maître d'enseignement et de recherche suppléant (50%)	50% Abdominal and transplant surgery (Geneva University Hospital)
	Chef de clinique (50%)	50% Cell isolation and transplantation center (Department of Surgery-Geneva)
Oct. 03-Oct. 05	Chef de clinique scientifique (50%)	50% Abdominal and transplant surgery (Geneva University Hospital)
	Chef de clinique (50%)	50% Cell isolation and transplantation center (Department of Surgery-Geneva)
Oct. 02-Oct. 03	Chef de clinique	Uster hospital (Zurich, Switzerland)- general surgery
Dec. 01-Oct. 02	Chef de clinique	Yverdon hospital (Vaud, Switzerland)- general surgery
Aug. 99-Dec.01	Interne	Cell isolation and transplantation center (Department of Surgery-Geneva): clinical and experimental (human, mouse, rat, pig) islet transplantations, microencapsulation, transplantation immunology, ischemia-reoxygenation model of liver sinusoidal endothelial cells, hepatocyte isolation.
Oct.97-Jul. 99	Interne	General surgery (Geneva University): Abdominal and Transplant surgery, Emergency, Thoracic Surgery, Orthopedics

Teaching and mentoring

Pre-graduate teaching:

In charge of the clinical (AMC) surgical training of medical students at the University of Geneva since 2009 (design and management of teaching and exams)

Member of the “Comité du Programme Master” at the University of Geneva

Member of the “Bureau du Programme Master” at the University of Geneva

Member of the “Comité Contenu du Curriculum” at the University of Geneva (reassessment of the current medical teaching at the University of Geneva)

Post-graduate teaching:

About 10 hours of post-graduate teaching /year

Mentoring of internes and chefs-de-clinique in the operating theater

Supervision of MD-PhD students (please see under Thesis supervision for other students):

- Graziano Oldani MD 2011-2015 (supported by a bridge-to-academic career grant 2013)
- Lorenzo Orci MD 2013-2016 (supported by a Swiss National Science Foundation PhD student bursary and the Geneva Cancer Foundation)
- Vaihere Delaune MD 2015-2018

Research

Research areas:

- Management of liver cancer by liver surgery and liver transplantation
- Immune clearance of liver cancer
- Xenogeneic chimeric mouse/rats using injections of iPS cells into blastocysts for immunosuppression-free liver transplantation
- Choledocholithiasis

Research groups:

Basic research group:

- Stéphanie Lacotte, PhD (maître-assistante, immunologist)
- Graziano Oldani, MD (MD-PhD, chef-de-clinique scientifique until Fall 2017)
- Lorenzo Orci, MD (MD-PhD, chef-de-clinique scientifique starting Fall 2017)
- Vaihere Delaune (MD-PhD student)
- Arianna Kahler-Quesada (research fellow)
- Florence Slits (technician)
- Quentin Gex (technician)

Clinical activity

- General abdominal open, laparoscopic and robot-assisted surgery (elective and emergency patients)
- Special expertise in liver and pancreas surgery (open and minimally-invasive)
- Transplantation of liver, kidney, pancreas and islets

Administrative duties

Member of the "Commission R2" since 2014

Member of the scientific committee of the "Prix de la Journée de la recherche clinique" since 2015

Member of the organizing committee "Journée et Prix Gilles Mentha" since 2015

Member "Comité de pilotage pour la chirurgie à 10 ans"

Member "Groupe de travail pour redéfinir les urgences chirurgicales"

Member "Comité de pilotage BDL2" for the Department of surgery

Member of a number of other "commissions" detailed under teaching and mentoring (including being in charge of the AMC of surgery)

Foundation de Reuter: member of the scientific council

Foundation Protransplant: member of the foundation council

Foundation Insuléman: member of the foundation council

Awards

Awards as a first author:

Astellas award 2017. 30'000 CHF

Swiss Transplantation meeting, Thoune, 2018

Prix Riotton 2016. 2'500 CHF

Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: A prospective validation.

University of Geneva, 2016

Vanguard Award at the International Liver Transplantation Society meeting 2015. 1500 USD

Pre-retrieval reperfusion decreases cancer recurrence after rat ischemic liver graft transplantation

Chicago, USA, 2015

Best Oral Award at the International Hepato-Pancreato-Biliary Association meeting 2014.

700 USD

Validation of a dropout assessment model of candidates with/without hepatocellular carcinoma on a common liver transplant waiting list

Seoul, Korea, 2014

Swiss Transplant Award 2013 (third price). 1'000 CHF

A model for dropout assessment of candidates with or without hepatocellular carcinoma on a common liver transplant waiting list

Interlaken, Switzerland, 2013

Senior Hepatology Award, 10'000 CHF

Award of the Swiss Gastro-Intestinal and Hepatology Society

Interlaken, Switzerland, 2012

Prix Bizot 2011 (for the best privat docent thesis at the University of Geneva). 2'500 CHF

Liver transplantation for the treatment of hepatocellular carcinoma.

University of Geneva, 2011

Swiss Surgical Society Award 2010. 5'000 CHF
Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepato-cellular carcinoma.
Interlaken, Switzerland, 2010

Swiss Transplant Award 2010 (third price). 2'000 CHF
Reassessing Selection Criteria Prior to Liver Transplantation for Hepatocellular Carcinoma with the Scientific Registry of Transplant Recipients Database
Interlaken, Switzerland, 2010

Swiss Transplant Award 2009 (third price). 2'000 CHF
Total Tumor Volume Can Predict Outcome after Transplantation for Hepatocellular Carcinoma
Interlaken, Switzerland, 2009

Trainee award at the Canadian Transplant Society. 1'000 CAD
Total Tumor Volume and Alpha-fetoprotein Can Best Predict Outcome after Transplantation for Hepatocellular Carcinoma: A Registry-based Study
Banff, Canada, 2009

Travel award at the Genzyme Transplant Academy Training Day.
Total Tumor Volume and Alpha-fetoprotein Can Best Predict Outcome after Transplantation for Hepatocellular Carcinoma: A Registry-based Study
Banff, Canada, 2009

Tom Williams Award. 500 CAD
Macrophage Migration Inhibitory Factor-deficiency improves outcomes after islet transplant in mice.
Edmonton, Canada, 2008

Travel award at the International Pancreas and Islet Transplant Association (IPITA) meeting.
1'500 USD
Impact of Macrophage Migration Inhibitory Factor (MIF) on islet engraftment.
Minneapolis, MI, September 2007

Young Investigator award at the World Transplant Congress (WTC). 1'000 USD
Clinical magnetic resonance imaging of allogeneic islet grafts after iron-labeling.
Boston, MA, USA, July 2006

Travel award at the Islet imaging NIH workshop. 500 USD
Positron-emission tomography imaging of early events and rejection after transplantation of islets of Langerhans.
Washington DC, USA, April 2006

M.-C. Marti award. 5'000 CHF
Positron-emission tomography imaging of early events after transplantation of islets of Langerhans.
Geneva, Switzerland, April 2005

Poster award at the Swiss Congress of the Abdominal Surgery Society.
Management of hepatocellular adenoma: solitary-uncomplicated, multiple and ruptured tumors.
Montreux, Switzerland, September 2004

Awards as a senior author

Pouya Iranmanesh MD: Research award 2017 of the Swiss Abdominal Surgery Society. 10'000 CHF

Prospective validation of an initial cholecystectomy strategy for patients at intermediate-risk of common bile duct stone

Lausanne, Switzerland, 2017

Graziano Oldani MD, PhD: Association for Research in Surgery at the Swiss Surgical Society meeting. 5000 CHF

Orthotopic liver transplantation of xenogeneic livers repopulated with autologous hepatocytes: Proof of normal function and consistent survival

Bern, Switzerland, 2017

Lorenzo Orci MD, PhD: Award of the British Journal of Surgery at the Swiss Surgical Society meeting. 1000 CHF

Effect of ischaemic preconditioning on recurrence of hepatocellular carcinoma in an experimental model of liver steatosis

Bern, Switzerland, 2017

Lorenzo Orci MD, PhD: Arditi award 2017 (for the best MD-PhD thesis at the University of Geneva)

Geneva, Switzerland, 2017

Lorenzo Orci MD, PhD: Gilles Mentha award. 5000 CHF

Effects of the gut-liver axis on ischemia-mediated hepatocellular carcinoma recurrence in the mouse liver

Geneva, Switzerland, 2016

Lorenzo Orci MD, PhD: Award of the British Journal of Surgery at the Swiss Surgical Society meeting. 1000 CHF

Donor characteristics and risk of hepatocellular carcinoma recurrence after liver transplantation

Lugano, Switzerland, 2016

Pouya Iranmaesh MD: Gilles Mentha award at the University of Geneva. 5000 CHF

A prospective validation of the cholecystectomy first strategy for the management of patients at risk of choledocholithiasis

Geneva, Switzerland, 2015

Lorenzo Orci MD, PhD student: Award of the British Journal of Surgery at the Swiss Surgical Society meeting. 1000 CHF

Systematic review and meta-analysis of percutaneous subclavian vein puncture versus surgical venous cutdown for the insertion of a totally implantable venous access device

Bern, Switzerland, 2015

Pouya Iranmanesh MD: Zollikofer award 2015 from the Swiss Association for Laparoscopic and Thoracoscopic Surgery (SALTC). 3000 CHF

Initial cholecystectomy versus sequential common bile duct endoscopic assessment and subsequent cholecystectomy for suspected gallstone migration: a randomized clinical trial

Bern, Switzerland, 2015

Pouya Iranmanesh MD: "Prix de la recherche Clinique" at Geneva University Hospitals. Best clinical study 2015. 1000 CHF

Initialcholecystectomy versus sequential common bile duct endoscopic assessment and subsequent cholecystectomy for suspected gallstone migration: a randomized clinical trial
Geneva, Switzerland, 2015

Lorenzo Orci MD, PhD student: Young investigator Award at the European Association for the Study of Liver (EASL). 650 Euros

Ischemic preconditioning of injured steatotic livers reduces hepatocellular carcinoma recurrence

Vienna, Austria, April 2015

Lorenzo Orci MD, PhD student: Young investigator Award at the European Association for the Study of Liver (EASL). 650 Euros

Donor characteristics and the risk of hepatocellular carcinoma recurrence after liver transplantation

London, UK, April 2014

Lorenzo Orci MD, PhD student: Young investigator Award at the International Liver Transplantation Society meeting (ILTS). 1000 USD

Donor characteristics and the risk of hepatocellular carcinoma recurrence after liver transplantation

London, UK, June 2014

Pouya Iranmanesh MD: Young Investigator Award and Best oral at the Hepato-Pancreato-Biliary Association meeting 2014. 1000 USD

Initialcholecystectomy versus sequential common bile duct endoscopic assessment and subsequent cholecystectomy for suspected gallstone migration: a randomized clinical trial
Seoul, South Korea, 2014

Lorenzo Orci MD, PhD student: Ethicon Travel Award, Swiss Gastroenterology Society meeting. 750 CHF

Donor characteristics and the risk of hepatocellular carcinoma recurrence after liver transplantation

Interlaken, Switzerland, September 2013

Pouya Iranmanesh MD: Joined award of the Swiss Gastroenterology Society and of the Swiss Abdominal Surgery Society. 7500 CHF

Initialcholecystectomy versus sequential common bile duct endoscopic assessment and subsequent cholecystectomy for suspected gallstone migration: a randomized clinical trial

Basel, Switzerland, 2013

Stéphanie Lacotte PhD: Poster Award of the Swiss Surgical Society. 1250 CHF

Alloimmune activation promotes anti-cancer cytotoxicity after rat liver transplantation

Davos, Switzerland, June 2012

Societies and Congress organization

Member of the European Surgical Association
Member of the "Compagnons hépato-biliaires" group

Board member of the Swiss Association of the Study of Liver (SASL)
Member of the scientific committee of the Swiss Transplant Society

Member of the Swiss Society of Surgery
Member of the Swiss Society of Abdominal Surgery (past Board member)
Member of the Research Section of the Swiss Society of Surgery
Member of the European Society of Organ Transplantation
Member of the International Hepato-pancreato-biliary association (IHPBA)
Member of the European Association for the study of liver disease (EASL)

Secretary of the International Hepato-pancreato-biliary association (IHPBA) meeting, Geneva 2018
Treasurer of the ESOT conference, Geneva 2005 (European Society of Transplantation)
Member of the local organizing committee of IPITA, Geneva 2005 (International Pancreas/ Islet Transplant Association)

Editorial board memberships, Reviews

Editorial Board memberships:

Transplantation Proceedings (Journal of the International Transplant Society)
World Journal of Gastroenterology (Contributing Associate Editor-in-Chief 2014-2017)
World Journal of Transplantation (Editorial Board Member)

Manuscript reviews:

American Journal Transplantation (Impact factor: 6.8)
Annals of Surgery (Impact factor: 8.5)
Biomaterials (Impact factor: 4.7)
BMC Gastroenterology (Impact factor: 2.1)
Diabetes-Metabolism Research and Review (Impact factor: 3.1)
Journal of American Medical Association (Impact factor: 28.9)
Journal of Hepatology (Impact factor: 7.1)
Hepatology (Impact factor: 10.8)
Liver Transplantation (Impact factor: 4.6)
Molecular Therapy (Impact factor: 5.4)
Pediatric Transplant (Impact factor: 1.5)
The Lancet (Impact factor: 30.8)
Transplantation (Impact factor: 4)
Transplant International (Impact factor: 2.1)
Transplantation Proceedings (Impact factor: 1)
World Journal of Gastroenterology (Impact factor: 2.2)

Grant reviews:

Agence Nationale de la Recherche (ANR), France
Czech Science Foundation, National Czech Research Founding agency
Canadian Institutes of Health Research, National Canadian Research Founding agency
European Society of Organ Transplantation (ESOT), Europe
South Plains Foundation, Lubbock, Texas

Grants

Insuléman Foundation, Switzerland 2017

Immune modulation in pancreatic islet transplantation
Lacotte S., Delaune V., Toso C. 51'000.- (Swiss Francs)

PRD 10-2016-I Geneva Hospitals project. *Establishing a new allocation system of liver grafts based on expected candidate survival benefit*
Andres A., Greiner R., Montano-Loza A., Combescure C., Morel P., Kneteman N., Toso C. 25'000.- (Swiss Francs)

Swiss National Science Foundation Professorship Extension: PP00P3_165837, 2017-2018
Surgical management of hepatocellular carcinoma
Toso C. 745'589.- (Swiss Francs)

Ligue genevoise contre le cancer 2016-2019
Traitement chirurgical des patients avec carcinome hépato-cellulaire
Toso C., Lacotte S., Oldani G., Orci L., Delaune V. 329'026.- (Swiss francs)

Fondazione per la ricerca sulla trasfusione e i sui trapianti 2014-2015
Mechanisms of extra-hepatic hepatocellular carcinoma recurrence after liver transplantation
Orci L.A., Lacotte S., Oldani G., Toso C. 40'000.- (Swiss francs)

Emmanuel Gomarín Foundation 2013
Assessing the risk of cancer recurrence after liver transplantation for hepatocellular carcinoma
Lacotte S., Oldani G., Orci L.A., Toso C. 10'000.- (Swiss francs)

Minkoff Foundation, 2013-2016
Islet transplantation from chimeric donors with recipient-tailored pancreas
Oldani G., Lacotte S., Orci L.A., Toso C. 108'350.- (Swiss francs)

Artères Foundation, 2013
Zero recurrence project
Toso C., Majno P., Lacotte S., Mentha G., Rubbia-Brandt L., McKee T., Lin-Marq N., Terraz S., Breguet R., Becker C. 49'450.- (Swiss francs)

Carigest, 2013
Assessing the risk of cancer recurrence after liver transplantation for hepatocellular carcinoma with the use of grafts from donors after cardiac death
Lacotte S., Oldani G., Orci L., Toso C. 59'000 CHF

Swiss National Science Foundation Professorship: PP00P3_139021, 2013-2016
Adjuvant management after liver transplantation for hepatocellular carcinoma
Toso C. 1'475'939.- (Swiss Francs)

Boninchi Foundation, 2011
Adjuvant immune management after liver transplantation for hepatocellular carcinoma
Toso C., Lacotte S. 71'000.- (Swiss Francs)

Astellas Foundation Europe Grant 2011
Towards a better immunosuppression after liver transplantation for hepatocellular carcinoma
Toso C., Lacotte S., Mentha G. 300'000 USD

Insuléman Foundation, Switzerland 2011
Towards an accurate post-transplant islet graft immune monitoring: a prospective clinical study
Toso C., Lacotte S. 50'000.- (Swiss Francs)

Artères Foundation, 2011-2014

Zero recurrence project

Toso C., Majno P., Lacotte S., Mentha G., Rubbia-Brandt L., McKee T., Lin-Marq N., Terraz S., Breguet R., Becker C. 289'000.- (Swiss francs)

Foundation "Projets Recherche & Développement" (Geneva), November 2009

Liver transplantation monitoring measuring peripheral lymphocyte reactivity against liver tissue

Toso C, Hadengue A., Mentha G.: 30'000.- (Swiss francs)

Swiss National Science Foundation: SCORE (Swiss Clinicians Opting For Research):

323230_126233, 2010-1013

Islet transplantation monitoring measuring CD8+ lymphocyte reactivity against β -cell peptides

Toso C: 717'571.- (Swiss francs)

Fondation pour la lutte contre le cancer et pour des recherches medico-biologiques, 2006

Post-transplant monitoring of islet grafts

Berney T., Toso C., Morel P: 150'000.- (Swiss francs)

NIH, National Institute of Diabetes and Digestive and Kidney Diseases: RFA # RFA-DK-06-003, 2006

Islet of Langerhans graft monitoring by magnetic resonance imaging

Berney T, Vallée JP, Toso C, Bosco D, Benhamou PY, Secchi A, Bertuzzi F, Morel P: 650'000 USD

Swiss National Foundation for Scientific Research: 3200B0-113899, 2006

Islet graft monitoring by magnetic resonance imaging

Berney T, Vallée JP, Bosco D, Toso C: 197'000.- (Swiss francs)

Foundation "Projets Recherche & Développement" (Geneva), September 2003

Transplantation of islets of Langerhans: study of early post-transplant events by positron-emission tomography imaging

Toso C, Slosman D., Berney T., Morel P: 50'000.- (Swiss francs)

Scholarships, Fellowships

Swiss National Sciences Foundation fellowship: PASM33-118593: 45'000 CAD

Transplantation d'îlots de Langerhans: améliorer et suivre par radiologie l'implantation et la survie.

Federal fellowship, Switzerland, 2007-2008

Alberta Heritage Foundation in Medical Research (AHFMR) fellowship: 45'000 CAD

Islet transplantation: study of the role of Macrophage Migration Inhibitory Factor on engraftment.

Alberta, Canada, 2007-2009

FS Chia award PhD Scholarship. Free PhD tuitions.

University of Alberta, Edmonton, Canada, 2007-2009

Fond de perfectionnement. 30'000.- (Swiss francs)

University Hospital, Geneva, Switzerland, 2005

Thesis supervision

MD-PhD students:

- Graziano Oldani MD 2011-2014 (extra-muros student from the University of Pavia, Italy, supported by a bridge-to-academic career grant 2013)
- Lorenzo Orci MD 2013-2016 (supported by a Swiss National Science Foundation MD-PhD student bursary and the Geneva Cancer Foundation)
- Vaihere Delaune MD 2015-2018

Master thesis student:

- Oscar Vasquez 2013-2014
- Carolina Shore 2017-2018

Master in surgery:

- Noof Al Naimi 2015-2016

Master in Medical Research Methodology (Aristotle University of Thessaloniki), co-supervisor:

- Lefteris Gialamas 2016-2017

Original articles in peer-reviewed journals

1. Assalino M., Toso C., Berney T., Giraud R., Dutkowski P., Andres A., Wildhaber B., Majno P. *In-situ Split liver transplantation from brain-dead donors under Extra-Corporeal Membrane Oxygenation*
Am J Transplant 2017; in press (Impact factor 6.2)
2. Toso C., Pinto Marques H., Andres A., Castro Sousa F., Adam R., Kalil A., Clavien P.A., Furtado E., Barroso E., Bismuth H., on behalf of the “Compagnons hépato-biliaires” group *Liver transplantation for colo-rectal liver metastasis: survival without recurrence can be achieved*
Liver Transplantation 2017; in press (Impact factor 4)
3. Meier R., Toso C., Berney T., Bednarkiewicz M. *Surgical repair of a living-donor kidney graft artery kink by a post anastomotic external iliac artery rotation and re-anastomosis*
Ann Vasc Surg 2017; in press (Impact factor 1)
4. de Sousa S., Tobler O., Iranmanesh P., Frossard J.L., Morel P., Toso C. Management of suspected common bile duct stones on cholangiogram during same-stay cholecystectomy for acute gallstone-related disease
BMC surg 2017; 17(1): 39 (Impact factor 1.5)
5. Leboeuf C., Wilk S., Achermann R., Binet I., Golshayan D., Hadaya K., Hirzel C., Hoffmann M., Huynh-Do U., Koller M.T., Manuel O., Mueller N.J., Mueller T.F., Schaub S., van Delden C., Weissbach F.H., Hirsch H.H.; Swiss Transplant Cohort Study *BK Polyomavirus-Specific 9mer CD8 T Cell Responses Correlate With Clearance of BK Viremia in Kidney Transplant Recipients: First Report From the Swiss Transplant Cohort Study*
Am J Transplant 2017; in press (Impact factor 5.7)
6. Vigano L., De Rosa G., Toso C., Andres A., Ferrero A., Roth A., Sperti E., Majno P., Rubbia-Brandt L. *Reversibility of Chemotherapy-Related Liver Injuries*
J Hepatol 2017; in press (Impact factor 10.6)
7. Moussaoui D., Toso C., Nowacka Anna, McLin V.A., Bednarkiewicz M., Andres A., Berney T., Majno P., Wildhaber B. E. *Early complications after liver transplantation in children and adults: Are split grafts equal to each other and equal to whole livers?*
Ped Transplant 2017; in press (Impact factor 1.3)
8. Gialamas E., Balaphas A., Assalino M., Morel P., Toso C., Staszewicz W. *Complex abdominal wall defect repair using biologic porcine matrix*
Minerva Chir 2017; in press (Impact factor 0.9)
9. Orci L.A., Oldani G., Lacotte S., Slits F., Friedli I., Wirth W., Toso C., Vallée J.P., Crowe L.A. *Dynamic volume assessment of hepatocellular carcinoma in rat livers using a clinical 3T MRI and novel segmentation*
J Inv Surg 2017: 1-10 (Impact factor 1.2)
10. Beaume M., Köhler T., Greub G., Manuel O., Aubert J.D., Baerlocher L., Farinelli L., Buckling A., van Delden C. Swiss Transplant Cohort Study *Rapid adaptation drives invasion of airway donor microbiota by Pseudomonas after lung transplantation*
Sci Rep. 2017; 7: 40309 (Impact factor 5.2)

11. Morel P., Jung M., Cornateanu S., Buhler L., Majno P., Buchs N.C., Toso C., Rubbia-Brandt L., Hagen M. Robotic versus open liver resections: A case-matched comparison *Int J Med Robot* 2017; in press (Impact factor 1.5)
12. Benmohamed N., Abbassi Z., Naiken S.P., Morel P., Poletti P.A., Toso C. *Management of a complex pancreaticoduodenal lesion following a suicidal attempt with a crossbow: a case report* *J Surg Case Rep* 2017; 2016 (12)
13. Martin-Gandul C., Stampf S., Héquet D., Mueller N.J., Cusini A., van Delden C., Khanna N., Boggian K., Hirzel C., Soccac P., Hirsch H.H., Pascual M., Meylan P., Manuel O.; *Swiss Transplant Cohort Study Preventive Strategies Against Cytomegalovirus and Incidence of α -Herpesvirus Infections in Solid Organ Transplant Recipients: A Nationwide Cohort Study* *Am J Transplant* 2016; In press (Impact factor 5.7)
14. Beckmann S., Nikolic N., Denhaerynck K., Binet I., Koller M., Boely E., De Geest S.; Psychosocial Interest Group, Swiss Transplant Cohort Study. *Evolution of body weight parameters up to 3 years after solid organ transplantation: The prospective Swiss Transplant Cohort Study* *Clin Transplant* 2017; 31(3) (Impact factor 1.8)
15. Lacotte S., Slits F., Orci L.A., Meyer J., Oldani G., Delaune V., Gonelle-Gispert C., Morel P., Toso C. *Impact of myeloid-derived suppressor cell on Kupffer cells from mouse livers with hepatocellular carcinoma* *Oncol Immunology* 2016; 5(11): e1234565 (Impact factor 7.6)
16. Iranmanesh P., Tobler O., De Sousa S., Frossard J. L., Morel P., Toso C. *Prospective validation of an initial cholecystectomy strategy for patients at intermediate-risk of common bile duct stone* *Gastrointestinal Endoscopy* 2016; 85(4): 794-802 (Impact factor 6.2)
17. Mauthner O., Claes V., Walston J., Engberg S., Binet I., Dickenmann M., Golshayan D., Hadaya K., Huynh-Do U., Calciolari S., De Geest S.; GERAS study consortium; For the Psychosocial Interest Group; Swiss Transplant Cohort Study (STCS) ExplorinG frailty and mild cognitive impairment in kidney transplantation to predict biomedical, psychosocial and health cost outcomes (GERAS): protocol of a nationwide prospective cohort study. *J Adv Nurs* 2016; 73(3): 716-734 (Impact factor 1.9)
18. Oldani G., Lacotte S., Orci L.A., Delaune V., Slits F., Morel P., Rubbia-Brandt L., Toso C. *Efficient non-arterialized mouse liver transplantation using 3D-printed instruments* *Liver Transplant* 2016; 22(12): 1688-1696 (Impact factor 4.0)
19. Sapisochin G., Facciuto M., Rubbia-Brandt L., Marti J., Mehta N., Yao F., Vibert E., Cherqui D., Grant D.R., Hernandez-Alejandro R., Dale C., Cucchetti A., Pinna A., Hwang S., Lee S., Agopian V., Busuttill R., Rizvi S., Heimbach J., Montenegro M., Reyes J., Cesaretti M., Soubrane O., Reichman T., Seal J., Tw Kim P., Klintmalm G., Sposito C., Mazzaferro V., Dutkowski P., Clavien P.A., Toso C., Majno P., Kneteman N., Saunders C., Bruix J.; iCCAInternational Consortium. *Liver transplantation for "very early" intrahepatic cholangiocarcinoma. international retrospective study supporting a prospective assessment* *Hepatology* 2016; 64(4): 1178-88 (Impact factor 11.7)

20. Djaafar S., Dunand-Sautier I., Gonelle-Gispert C., Lacotte S., Majno P., Rubbia-Brandt L., Morel P., Toso C., Mentha G. *Enoxaparin attenuates mouse colon cancer liver metastases by inhibiting heparanase and IFN γ -inducible chemokines*
Anticancer Research 2016; 36(8): 4019-4032 (Impact factor 1.8)
21. Héquet D., Kralidis G., Carrel T., Cusini A., Garzoni C., Hullin R., Meylan P.R., Mohacsi P., Mueller N.J., Ruschitzka F., Tozzi P., van Delden C., Weisser M., Wilhelm M.J., Pascual M., Manuel O.; Swiss Transplant Cohort Study (STCS) *Ventricular assist devices as bridge to heart transplantation: impact on post-transplant infections*
BMC Infect Dis. 2016;16(1): 321 (Impact factor 2.7)
22. Delaune V., Toso C., Benhamou P.Y., Wojtuszczyzn A., Kessler L., Slits F., Demuylder-Mischler S., Lablanche S., Orci L.A., Oldani G., Morel P., Berney T., Lacotte S. *Allo-immune monitoring after islet transplantation: a prospective multicenter assessment of 25 recipients*
Cell Transplant 2016; 25(12):2259-2268 (Impact factor 3.1)
23. De Vito C., Rubbia-Brandt L., Toso C. *Unexpected steatotic liver lesions*
Gastroenterology 2016; 151(1): 32-3 (Impact factor 16.7)
24. Al-Naimi N., Abbassi Z., Pacifique J. X., Rougemont-Pidou A.-L., Surennaidoo P., Naiken S.P., Erne E., Morel P., Toso C. *Colic PEComa: one disease, two outcomes*
Int J Colorectal Dis 2016; 31(9): 1661-3 (Impact factor 2.5)
25. Gariani K., Toso C., Philippe J., Orci L. *Impact of liver transplantation on endocrine function: A systematic review*
Liver Int 2016; 36(10): 1401-11 (Impact factor 4.9)
26. Orci L.A., Gariani K., Oldani G., Delaune V., Morel P., Toso C. *Exercise-based lifestyle interventions for non-alcoholic fatty liver disease: a meta-analysis and meta-regression*
Clinical Gastroenterology and Hepatology 2016; 14(10): 1398-411 (Impact factor 7.89)
27. Calmy A., van Delden C., Giostra E., Junet C., Rubbia Brandt L., Yerly S., Chave J.P., Samer C., Elkrief L., Vionnet J., Berney T.; Swiss HIV and Swiss Transplant Cohort Studies *HIV-Positive-to-HIV-Positive Liver Transplantation*
Am J Transplant 2016; 16(8): 2473-8 (Impact factor 5.7)
28. Niclauss N., Bédât B., Morel P., Andres A., Toso C., Berney T. *Impact of graft implantation order on graft survival in simultaneous pancreas-kidney transplantation*
Transplant Int 2016 ; 29(5): 627-635 (Impact factor 2.8)
29. Golshayan D., Wójtowicz A., Bibert S., Pyndiah N., Manuel O., Binet I., Buhler L.H., Huynh-Do U., Mueller T., Steiger J., Pascual M., Meylan P., Bochud P.Y.; Swiss Transplant Cohort Study. *Polymorphisms in the lectin pathway of complement activation influence the incidence of acute rejection and graft outcome after kidney transplantation*
Kidney Int. 2016 ; 89(4): 927-938 (Impact factor 8.6)
30. Orci L.A., Lacotte S., Oldani G., Slits F., De Vito C., Crowe L.A., Rubbia-Brandt L., Vallée J.P., Morel P., Toso C. *Ischaemic preconditioning of injured steatotic mouse livers reduces hepatocellular carcinoma recurrence*
Br J Surg. 2016; 103(4): 417-26 (Impact factor 5.6)
31. Hansen C., Ronot M., Toso C., Rubbia-Brandt L., Boudabbous S., Terraz S. *Endobiliary hepatocellular carcinoma: A rare tumor mimicking cholangiocarcinoma*
Diagn Interv Imaging 2016 ; 97(3): 365-367 (Impact factor 1.4)

32. Quteineh L., Bochud P.Y., Golshayan D., Crettol S., Venetz J.P., Manuel O., Kutalik Z., Treyer A., Lehmann R., Mueller N.J., Binet I., van Delden C., Steiger J., Mohacsi P., Dufour J.F., Soccal P.M., Pascual M., Eap C.B.; and The Swiss Transplant Cohort Study *CRTC2 polymorphism as a risk factor for the incidence of metabolic syndrome in patients with solid organ transplantation*
Pharmacogenomics 2015; in press (Impact factor 4.2)
33. Vitali G., Laurent A., Terraz S., Majno P., Buchs N., Rubbia-Brandt L., Luciani A., Calderaro J., Morel P., Azoulay D., Toso C. *Minimally-invasive surgery versus percutaneous radiofrequency ablation for the treatment of single small (≤ 3 cm) hepatocellular carcinoma: a case-control study*
Surg Endosc 2015; in press (Impact factor 3.3)
34. Meier R.P.H., Toso C., Terraz S., Breguet R., Berney T., Andres A., Jannot A.S., Rubbia-Brandt L., Morel P., Mentha G., Majno P.E. *Improved liver function after portal vein embolization and elective right hepatectomy*
HPB 2015; 17(11): 1009-18 (Impact factor 2.9)
35. Gialamas L., Oldani G., Madarressi-Ghavami A., Morel P., Toso C. *Liver Trauma During Combined Liposuction and Abdominoplasty: A Rare But Potentially Lethal Complication*
Aesthet Surg J 2015; 35(7): NP211-5 (Impact factor 1.8)
36. Orci L.A., Berney T., Majno P.E., Lacotte S., Oldani G., Morel P., Mentha G., Toso C. *Donor characteristics and the risk of hepatocellular carcinoma recurrence after liver transplantation*
Br J Surg. 2015; 102(10): 1250-7 (Impact factor 5.6)
37. Wójtowicz A., Lecompte T.D., Bibert S., Manuel O., Rüeger S., Berger C., Boggian K., Cusini A., Garzoni C., Hirsch H., Khanna N., Mueller N.J., Meylan P.R., Pascual M., van Delden C., Bochud P.Y. and the Swiss Transplant Cohort Study (STCS) *PTX3 Polymorphisms and Invasive Mold Infections after Solid Organ Transplantation*
Clin Infect Dis 2015; 21(8): 1076-81 (Impact factor 8.9)
38. Orci L.A., Meyer J., Combescure C., Bühler L., Berney T., Morel P., Toso C. *A meta-analysis of extended versus standard lymphadenectomy in patients undergoing pancreatoduodenectomy for pancreatic adenocarcinoma*
HPB 2015; 17(7): 565-72 (Impact factor 2.9)
39. Kaseje N., McLin V., Toso C., Poncet A., Wildhaber B. *Donor hypernatremia prior to procurement and early outcomes following pediatric liver transplantation*
Liver Transplant 2015; 21(8): 1076-81. (Impact factor 4.2)
40. Vigano L., Rubbia-Brandt L., De Rosa G., Majno P., Langella S., Toso C., Mentha G., Capussotti L. *Nodular regenerative hyperplasia in patients undergoing liver resection for colorectal metastases after chemotherapy. Risk factors, preoperative assessment and clinical impact*
Ann Surg Oncol 2015; in press (Impact factor 3.9)
41. Andres A., Mentha G., Adam R., Gerstel E., Skipenko O.G., Barroso E., Lopez-Ben S., Hubert C., Majno P.E., Toso C. *Surgical management of patients with colorectal cancer and simultaneous liver and lung metastases*
Br J Surg. 2015; 102(6): 691-9 (Impact factor 5.6)

42. Toso C., Meeberg G., Hernandez-Alejandro R., Dufour J.F., Marotta P., Majno P., Kneteman N.M. *Total Tumour Volume and Alpha Fetoprotein for selection of transplant candidates with hepatocellular carcinoma: a prospective validation* Hepatology 2015; 62(1): 158-65 (Impact factor 11.1)
43. Viganò L., Capussotti L., Majno P., Toso C., Ferrero A., De Rosa G., Rubbia-Brandt L., Mentha G. *Liver resection in patients with eight or more colorectal liver metastases* Br J Surg. 2015; 102(1): 92-101 (Impact factor 5.6)
44. Giovannoni L., Muller Y., Lacotte S., Morel P., Parnaud G., Niclauss N., Borot S., Meier R., Lavallard V., Bédât B., Toso C., Daubeuf B., Elson G., Shang L., Kosco-Vilbois M., Bosco D., Berney T. *Enhancement of islet engraftment and achievement of long-term islet allograft survival by toll-like receptor 4 blockade* Transplantation 2014; 99(1): 29-35 (Impact factor 3.8)
45. Calinescu A.M., Wildhaber B.E., Poncet A., Toso C., McLin V.A. *Outcomes of combined liver-kidney transplantation in children: analysis of the Scientific Registry of Transplant Recipients.* Am J Transplant 2014; 14(12): 2861-2868 (Impact factor 5.7)
46. Lüthold S.C., Kaseje N., Jannot A.-S., Mentha G., Majno P., Toso C., Belli D.C., McLin V.A., Wildhaber B.E. *Risk factors for early and late biliary complications in pediatric liver transplantation* Pediatric Transplantation 2014; 18(8): 822-830 (Impact factor 1.4)
47. Buchs N.C., Ris F., Majno P.E., Andres A., Cacheux W., Gervaz P., Roth A.D., Terraz S., Rubbia-Brandt L., Morel P., Mentha G., Toso C. *Rectal outcomes after a liver-first management of patients with stage IV rectal cancer* Annals of Surgical Oncology 2014; 22(3): 931-937 (Impact factor 3.9)
48. *Iranmanesh P., Frossard J.L., Mugnier-Konrad B., Morel P., Majno P., Nguyen T., Berney T., Mentha G., Toso G. *Initial cholecystectomy versus sequential common bile duct endoscopic assessment and subsequent cholecystectomy for suspected gallstone migration: a randomized clinical trial* JAMA 2014; 312(2): 137-44 (Impact factor 35.3)
Reply to letter to Editor: Iranmanesh P., Frossard J.L., Toso C. *Treatment for patients at intermediate risk of a common duct stone-reply* JAMA 2014 ;312(19): 2043-2044 (Impact factor 35.3)
Reply to letter to Editor: Iranmanesh P., Frossard J.L., Toso C. *Surgery or endoscopy first for suspected bile duct stone?* Gastroenterology 2015;148(1): 252 (Impact factor 16.7)
49. Bédât B., Niclauss N., Jannot A.S., Andres A., Toso C., Morel P., Berney T. *Impact of Recipient Body Mass Index on Short-Term and Long-Term Survival of Pancreatic Grafts* Transplantation 2014; 99(1): 94-9 (Impact factor 3.8)
50. Meier R., Sert I., Morel P., Muller Y.D., Borot S., Badet L., Toso C., Bosco D., Berney T. *Islet of Langerhans isolation from pediatric and juvenile donor pancreases* Transplant Int 2014; 27(9): 949-955 (Impact factor 2.6)
51. Lablanche S., Borot S., Thaunat O., Bayle F., Badet L., Morelon E., Thivolet C., Wojtuszczyzn A., Frimat L., Kessler L., Penfornis A., Brault C., Colin C., Bosco D., Berney T., Benhamou P.Y.; GRAGIL Network *Impact of anti-insulin antibodies on islet transplantation outcome: data from the GRAGIL Network.* Transplantation 2014; 98(4): 475-482 (Impact factor 3.8)

52. *Oldani G., Crowe L.A., Orci L. A., Slits F., Rubbia-Brandt L., de Vito C., Morel P., Mentha G., Berney T., Vallée JP, Lacotte S., Toso C. *Pre-retrieval graft reperfusion decreases cancer recurrence after ischemic rat liver transplantation*
J Hepatol 2014; 61(2): 278-285 (Impact factor 11.3)
Reply to letter to Editor: Oldani G., Orci L.A., Lacotte S., Toso C. "Pre-retrieval reperfusion decreases cancer recurrence after rat ischemic liver graft transplantation"
J Hepatol 2014; 61(4): 962-963 (Impact factor 11.3)
53. Kashkoush S., El Moghazy W., Kawahara T., Gala-Lopez B., Toso C., Kneteman N.M. *Three-dimensional Tumor Volume and Serum Alphafetoprotein are Predictors of Hepatocellular Carcinoma Recurrence after Liver Transplantation: Refined Selection Criteria*
Clin Transplant 2014; 28(6): 728-36 (Impact factor 1.5)
54. Lacotte S., Oldani G., Slits F., Orci L.A., Rubbia-Brandt L., Morel P., Mentha G., Toso C. *Alloimmune activation promotes anti-cancer cytotoxicity after rat liver transplantation*
PLOS ONE 2014; 9(3):e91515. (Impact factor 3.2)
55. Toso C., Majno P., Berney T., Morel P., Mentha G., Combescure C. *Validation of a dropout assessment model of candidates with/without hepatocellular carcinoma on a common liver transplant waiting list*
Transplant Int 2014; 27(7): 686-95 (Impact factor 2.6)
56. Naiken S.P., Toso C., Rubbia-Brandt L., Thomopoulos T., Roth A., Mentha G., Morel P., Gervaz P. *Complete pathological response (ypT0N0M0) after preoperative chemotherapy alone for stage IV rectal cancer*
BMC Surgery 2014; 14(1): 4 (Impact factor 1.4)
57. Iranmanesh P., Vazquez O., Terraz S., Majno P., Spahr L., Poncet A., Morel P., Mentha G., Toso C. *Accurate computed tomography-based portal pressure assessment in patients with hepatocellular carcinoma*
J Hepatol 2013; 60(5): 969-974 (Impact factor 11.3)
Reply to letter to Editor: Iranmanesh P., Poncet A., Toso C "Virtual portal pressure from anatomic CT angiography"
J Hepatol 2013; 61(1):182 (Impact factor 11.3)
58. Thomopoulos T., Meyer J., Staszewicz W., Bagetakos I., Scheffler M., Lomessy A., Toso C., Becker C.D., Morel P. *Routine chest X-ray is not mandatory after fluoroscopy-guided totally implantable venous access device insertion*
Ann Vasc Surg 2014; 28(2): 345-350 (Impact factor 1.2)
59. Morard I., Gasche Y., Kneteman M., Toso C., Mentha A., Meeberg G., Mentha G., Kneteman N., Giostra E. *Identifying risk factors for central pontine and extrapontine myelinolysis after liver transplantation: a case-control study*
Neurocritical Care 2014; 20(2):287-295 (Impact factor 3.0)
60. Majno P.E., Mentha G., Toso C., Morel P., Peitgen H.O. and Fasel J.D.H. *Anatomy of the liver revisited: An outline with three levels of complexity*
J. Hepatol 2014; 60(3):654-662 (Impact factor 11.3)
61. Elkhafif N.M., Borot S., Morel P., Demuylder-Mischler S., Giovannoni L., Toso C., Bosco D., Berney T. *Endocrine Secretory Reserve and Proinsulin Processing in Recipients of Islet of Langerhans Versus Whole Pancreas Transplants*
Diabetes Care 2013; 36(11):3726-3731(Impact factor 8.1)

62. Cudalbu C., McLin V.A., Lei H., Duarte J.M.N., Rougemont A-L., Oldani G., Terraz S., Toso C., Gruetter R. *The C57BL/6J mouse exhibits sporadic congenital portosystemic shunts*
PLOS ONE 2013; 8(7): e69782 (Impact factor 3.7)
63. Borot S., Crowe L.A., Parnaud G., Ris F., Meier R., Giovannoni L., Müller Y.D., Lacotte S., Morel P., Toso C., Bosco D., Vallee J.P., Berney T. *Quantification of islet loss and graft functionality during immune rejection by 3-Tesla MRI in a rat model*
Transplantation 2013; 96(5):438-444 (Impact factor 3.8)
64. Kawahara T., Toso C., Yamaguchi K., Cader S., Douglas D.N., Nourbakhsh M., Lewis J., Churchill T.A., Yagita H., Kneteman N.M. *Additive effect of sirolimus and anti-death receptor 5 agonistic antibody against hepatocellular carcinoma*
Liver Int 2013; 33(9):1441-1448 (Impact factor 4.4)
65. Klein J., Tran S.N., Mentha-Dugerdil A., Giostra E., Majno P., Morard I., Berney T., Dendauw P., Morel P., Mentha G., Iselin C.E., Toso C. *Assessment of sexual function and conjugal satisfaction prior to and after liver transplantation*
Clin Transplant 2013; 18: 136-145. (Impact factor 1.6)
66. Oldani G., Lacotte S., Orci L., Morel P., Mentha G., Toso C. *Manufacturing devices and instruments for easier rat liver transplantation*
J Vis Exp 2013 May 5; (75)
67. Buch N.C., Volonte F., Pugin F., Toso C., Fusaglia M., Ghavagan K., Majno P., Peterhans M., Weber S., Morel P. *Augmented environments for the targeting of hepatic lesions during robotic liver surgery*
J Surg Res 2013; 184(2): 825-31 (Impact factor 2)
68. Li N., Puga Yung G.L., Pradier A., Toso C., Giostra E., Morard I., Spahr L., Seebach J.D. *NK cells isolation from liver biopsies: phenotypic and functional analysis of low cell numbers by flow cytometry*
Frontiers in immunology 2013; 4: 61
69. Muller Y., Gupta S., Morel P., Borot S., Bettens F., Truchetet M.E., Villard J., Seebach J.D., Holmberg D., Toso C., Lobrinus J.A., Bosco D., Berney T. *Transplanted human pancreatic islets after long-term insulin independence.*
American Journal of Transplantation 2013; 13(4): 1093-1097 (Impact factor 6.2)
70. Papas K.K., Karatzas T., Berney T., Minor T., Pappas P., Pattou F., Shaw J., Toso C., Schuurman H.J. *Islet Transplantation without Borders: Enabling islet transplantation in Greece with international collaboration and innovative technology*
Clin Transplant 2013; 27(2): E116-25 (Impact factor 1.6)
71. Thomopoulos T., Mentha G., Toso C. *Image of the month- quiz*
JAMA Surg 2013;148(1):100 (Impact factor 4.1)
72. Orci L., Majno P., Berney T., Morel P., Mentha G., Toso C. *The impact of waitlist body mass index changes on the outcome after liver transplantation*
Transplant Int 2013; 26(2):170-176 (Impact factor 3.2)
73. Rossetti A., Bucher P., Buchs N.C., Morel P., Toso C. *The discovery of a choledochal cyst during a single-port cholecystectomy with intra-operative cholangiogram*
J. Med. Cases 2013; 4(2):114-115

74. Kaseje N., Luethold S., Mentha G., Majno P., Toso C., Belli D.C., McLin V., Wildhaber B.E. *Donor Hypernatremia Influences Outcomes Following Pediatric Liver Transplantation*
EJPS 2013; 23(1): 8-13 (Impact factor 0.8)
75. Wickboldt N., Pache J.C., Dietrich P.Y., Toso C., Gallay C., Brochard L., Merlani P., Pugin D. *Takotsubo syndrome secondary to adrenal adenocarcinoma. Cortisol as a possible culprit*
Am J Resp Crit Care 2012, 186(10):1061-2 (Impact factor 11)
76. Andres A., Toso C., Adam R., Barroso E., Hubert C., Capussotti L., Gerstel E., Roth A., Majno P.E., Mentha G. *A survival analysis of the liver-first reversed management of advanced simultaneous colorectal liver metastases: a LiverMetSurvey-based study*
Ann Surg 2012; 256(5): 772-779 (Impact factor 7.2)
77. Lacotte S., Borot S., Ferrari-Lacraz S., Villard J., Demuylder-Mischler S., Oldani G., Morel P., Mentha G., Berney T., Toso C. *Post-transplant cellular immune reactivity against donor-antigen correlates with clinical islet transplantation outcome: towards a better post-transplant monitoring*
Cell Transplantation 2012; 21(11): 2339-2350 (Impact factor 4.4)
78. Buchs N., Volonte F., Pugin F., Toso C., Morel P. *3D laparoscopy : a step towards advanced surgical navigation*
Surg Endo 2013; 27(2): 692-693 (Impact factor 3.4)
79. Oldani G., Lacotte S., Morel P., Mentha G., Toso C. *Orthotopic liver transplantation in rat*
J Vis Exp 2012; 65: 4143
80. Toso C., Cader S., Mentha-Dugerdil A., Meeberg G., Majno P., Morard I., Giostra E., Berney T., Morel P., Mentha G., Kneteman N.M. *Factors predicting survival after post-transplant hepatocellular carcinoma recurrence*
JHBPS 2013; 20(3): 342-347 (Impact factor 2.1)
81. Thomopoulos T., Naiken S., Rubbia-Brandt L., Mentha G., Toso C. *Management of a ruptured hydatid cyst involving the ribs: dealing with a challenging case and review of the literature*
Int J Surg Case Rep 2012; 3(7): 253-256
82. Ambrosioni J., Kaiser L., Giostra E., Meylan P., Mentha G., Toso C., Genevay-Infante M., Rubbia-Brandt L., van Delden C. *Herpes simplex virus load to monitor antiviral treatment after liver transplantation for acute herpetic hepatitis*
Antiviral Ther 2011; 17(2): 401-404 (Impact factor 3.1)
83. Toso C., Dupuis-Lozeron E., Majno P., Berney T., Kneteman N.M., Perneger T., Morel P., Mentha G., Combescure C. *A model for dropout assessment of candidates with or without hepatocellular carcinoma on a common liver transplant waiting list*
Hepatology 2012, 56(1): 149-156 (Impact factor 12)
84. Andres A., Gerstel E., Combescure C., Asthana S., Merani S., Majno P., Berney T., Morel P., Kneteman N., Mentha G., Toso C. *A score predicting the chance of survival after a second liver transplantation for hepatitis C virus cirrhosis*
Transplantation 2012; 93(7): 717-722 (Impact factor 3.8)

85. Westermarck, G.T., Davalli A.M., Secchi A., Folli F., Kin T., Toso C., Shapiro A.M.J., Korsgren O., Tufveson G., Andersson A., Westermarck P. Further evidence for amyloid deposition in clinical pancreatic islet grafts
Transplantation 2012; 93(2): 219-223 (Impact factor 3.8)
86. Assalino M., Genevay M., Morel P., Demuylder-Mischler S., Toso C., Berney T.
Recurrence of type 1 diabetes after simultaneous pancreas-kidney transplantation in the absence of GAD and IA-2 antibodies
American Journal of Transplantation 2012; 12(2): 492-495 (Impact factor 6.2)
87. Clavien P.A., Lesurtel M., Bossuyt P.M., Gores G.J., Langer B., Perrier A., OLT for HCC Consensus Group. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report
Lancet Oncol 2012; 13(1): e11-22 (Impact factor 25.12)
88. Merani S., McCall M.D., Pawlick R.L., Edgar R.L., Davis J., Toso C., Emamaullee J.A., Kin T., Shapiro A.M. *AEB071 (sotrastaurin) does not exhibit toxic effects on human islets in vitro, nor after transplantation into immunodeficient mice*
Islets 2011; 3(6): 338-343 (Impact factor 1.1)
89. Borot S., Niclauss N., Wojtuszczyz A., Barult C., Demuylder-Mischler S., Muller Y., Giovannoni L., Parnaud G., Meier R., Badet L., Bayle F., Frimat L., Kessler L., Morelon E., Penformis A., Thivolet C., Toso C., Morel P., Bosco D., Colin C., Benhamou P.Y., Berney T. *Impact of the number of infusions on two-year results of islet-after-kidney transplantation in the GRAGIL network*
Transplantation 2011; 92(9): 1031-1038 (Impact factor 4)
90. Toso C., Mentha G., Majno P. *Liver transplantation for hepatocellular carcinoma: five steps to prevent recurrence*
American Journal of Transplantation 2011; 11(10): 2031-2035 (Impact factor 6.4)
91. Hadaya K., Ferrari-Lacraz S., Fumeaux D., Boehlen F., Toso C., Moll S., Martin P.-Y. and Villard J. *Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation*
American Journal of Transplantation 2011, 11(11): 2523-2527 (Impact factor 6.4)
92. Andres A., Toso C., Morel P., Hauss-Meyer S., Rubbia-Brandt L., Terraz S., Schiffer E., Klopfenstein C., Majno P., Mentha G. *A score predicting the occurrence of morbidity and mortality after elective liver resection*
Archives of Surgery 2011; 146(11): 1246-1252 (Impact factor 4.2)
Andres A., Gerstel E., Majno P., Morel P., Toso C., Mentha G. Reply to Analytical concerns regarding complications of elective liver resections in a center with low mortality
Archives of Surgery 2011; 146(12): 11455-1456 (Impact factor 4.2)
93. Moldovan B., Mentha G., Majno P., Berney T., Morard I., Giostra V., Wildhaber B.E., Van Delden C., Morel P., Toso C. *Demographics and outcomes of severe herpes simplex virus hepatitis: a registry-based study*
J. of Hepatology 2011; 55(6): 1222-1226 (Impact factor 9.3)
94. McCall M., Toso C., Emamaullee J., Pawlick R., Edgar R., Davis J., Maciver A., Kin T., Arch R., and Shapiro AMJ. *The Caspase Inhibitor IDN-6556 (PF3491390) Improves Marginal Mass Engraftment after Islet Transplantation in Mice.*
Surgery 2011; 150: 48-55 (Impact factor 3.1)

95. Holzer T., Pellegrinelli G., Morel P., Toso C. *Appendectomy during the third trimester of pregnancy in a 27-year old patient: Case report of a near miss complication.*
Patient Safety in Surgery 2011 May 17;5(1):11
96. Crowe LA., Ris F., Nivelles-Vallespin S., Speier P., Masson S., Armanet M., Morel P., Toso C., Bosco D., Berney T., Vallee J.P. *A novel method for quantitative monitoring of transplanted islets of Langerhans by positive contrast magnetic resonance imaging.*
American Journal of Transplantation 2011; 11: 1158-1168 (Impact factor 6.4)
97. Lanitis A., Toso C. *Liver mass with central calcification*
Hepatology 2011; 53(4):1397-1398 (impact factor 11.7)
98. Niclauss N., Bosco D., Morel P., Demuylder-Mischler S., Brault C., Milliat-Guittard L., Colin C., Parnaud G., Muller Y.D., Giovannoni L., Meier R., Toso C., Badet L., Benhamou P.Y., Berney T. *Influence of donor age on islet isolation and transplantation outcome.*
Transplantation 2011; 91(3):360-366 (Impact factor 4)
99. Merani S., Majno P., Kneteman N.M., Berney T., Morel P., Mentha G., Toso C. *The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma*
J. Hepatol 2011; 55(4): 814-819 (impact factor 9.3)
100. Asthana S., Toso C., Meeberg G., Bigam D.L., Mason A., Shapiro A.M.J., Kneteman N.M. *The impact of sirolimus on Hepatitis C recurrence after liver transplantation*
Can. J. Gastroenterol. 2011;25(1):28-34 (Impact factor 1.2)
101. Lacotte S., Berney T., Shapiro A.M.J., Toso C. *Immune monitoring of pancreatic islet graft: toward a better understanding, detection and treatment of harmful events.*
Exp. Op. Biol. Ther. 2011; 11(1):55-66 (impact factor 3.6)
102. Toso C., Pawlick R., Lacotte S., Edgar E., Davis J., Mc Call M., Morel P., Mentha G., Berney T., Shapiro A.M.J. *Detecting rejection after mouse islet transplantation utilizing islet protein-stimulated ELISPOT.*
Cell Transplant. 2011; 20(6):955-62 (Impact factor 6.2)
103. Toso C., Mentha G., Majno P. *Selection of patients with hepatocellular carcinoma prior to liver transplantation: the need to combine alpha-fetoprotein to morphology?*
HBPD Int 2010;9(5):460-461 (Impact factor 1.2)
104. Majno P., Mentha G., Toso C. *Transplantation for hepatocellular carcinoma: management of patients on the waiting list.*
Liver Transplant 2010; 16(S2):S2-S11 (Impact factor 3.1)
105. Meier R., Toso C., Volonte F., Mentha G. *Splenic rupture after colonoscopy.*
American Journal of Emergency Medicine 2011; 29(2): 241e1-2 (Impact factor 1.5)
106. Ris F., Lepetit-Coiffé M., Meda P., Crowe L., Toso C., Armanet M., Bosco D., Morel P., Vallee J.P. and Berney T. *Assessment of iron nanoparticles for human islet labeling prior to transplantation and MRI monitoring*
Cell Transplantation 2010; 19(12):1573-1585 (Impact factor 6.2)
107. Kawahara T., Toso C., Douglas D., Lewis J., Lund G., Churchill T., Kneteman N.M. *Factors affecting hepatocyte isolation, engraftment, and replication in an in vivo model.*
Liver Transplantation 2010; 16(8):974-982 (Impact factor 3.1)

108. Serre-Beinier V., Toso C. (co first authors), Morel P., Gonelle-Gispert C., Veyrat-Durebex C., Rohner-Jeanrenaud F, Calandra T., Roger T., James RW, Montet X., Bühler L., Bosco D., Berney T. *Macrophage migration inhibitory factor-deficiency leads to age-dependent impairment of glucose homeostasis in mice*
Journal of Endocrinology 2010; 206(3):297-306 (Impact factor 3.1)
109. Klein J., Morel P., Toso C. *Calcifying bowel inflammation: a case report.*
Gastroenterology Research and Practice 2010; 2010:526486 (Impact factor 0.5)
110. Toso C., Mentha G., Kneteman N., Majno P. *The place of downstaging for hepatocellular carcinoma.*
J. of Hepatology 2010; 52(6):930-936 (Impact factor 9.3)
111. Emamaullee J.A., Davis J., Pawlick R., Toso C., Merani S., Cai S.X., Tseng B., and Shapiro A.M.J. *Caspase inhibitor therapy synergizes with costimulation blockade to promote indefinite islet allograft survival.*
Diabetes 2010, 59(6):1469-77 (Impact factor 8.9)
112. Low G., Hussein N., Owen R.J., Toso C., Patel V.H., Shapiro A.M.J. *The role of imaging in clinical islet cell transplantation.*
Radiographics 2010; 30(2): 353-366 (Impact factor 2.8)
113. Toso C., Merani S., Bigam D., Shapiro J., Kneteman N. *Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepato-cellular carcinoma.*
Hepatology, 2010; 51(4): 1237-1243 (Impact factor 10.9)
Editorial: Soll C., Clavien P.A. Inhibition of mammalian target of rapamycin: the janus face of immunosuppression. Hepatology 2010; 51(4): 1113-1115
114. Koh A., Senior P., Salam A., Kin T., Imes S., Dinyari P., Malcolm A., Toso C., Nilsson B., Korsgren O., Shapiro A.M. *Insulin-heparin infusions peritransplant substantially improve single-donor clinical islet transplant success.*
Transplantation 2010 Feb 27;89(4):465-71 (Impact factor 3.8)
115. Koh A., Imes S., Kin T, Dinyari P., Malcolm A., Toso C., Shapiro A.M., Senior P. *Supplemental islet infusions restore insulin independence after graft dysfunction in islet transplant recipients.*
Transplantation. 2010 Feb 15;89(3):361-5 (Impact factor 3.8)
116. Emamaullee, J.; Edgar, R.; Toso, C.; Thiesen, A.; Bain, V.; Bigam, D.; Kneteman, N.; Shapiro, J. *VEGF expression in hepatic epithelioid hemangioendothelioma: implications for treatment and surgical management*
Liver Transplantation 2010, 16(2):191-197 (Impact factor 3.1)
117. Asthana S., Toso C., Kawahara T., Bigam D., Kneteman N., McCarthy M., Shapiro A.M.J. *The management of splenic artery aneurysm in patients awaiting liver transplantation.*
Clinical Transplant 2011,24(5):691-694 (Impact factor 1.8)
118. Toso C., Patel S., Asthana S., Kawahara T., Girgis S., Kneteman N., Shapiro AMJ, Bigam DL. *The impact of sirolimus on hepatocyte proliferation after living donor liver transplantation.*
Clinical Transplant 2010,24(5):695-700 (Impact factor 2)

119. Toso C., Isse K., Demetris A.J., Dinyari P., Koh A., Imes S., Kin T., Emamaullee J., Senior P., Shapiro A.M.J. *Histological graft assessment after clinical islet transplantation.* Transplantation 2009; 88(11):1286-93 (Impact factor 3.5)
120. Toso C., Mc Call M., Emamaullee J., Merani S., Davis J., Edgar R., Pawlick R., Kin T., Knudsen L.B., Shapiro A.M.J. *Liraglutide, a long-acting human glucagon-like peptide 1 analogue, improves human islet survival in culture.* Transplant Int. 2009;23(3):259-65 (Impact factor 3.3)
Editorial: Berney T. Liraglutide in islet transplantation: from bench to bedside. Transplant Int ;23(3):257-8
121. McCall M., Toso C., Baetge E.E., Shapiro A.M.J. *Are stem cells a cure for diabetes?* Clinical Science 2009;118(2):87-97 (Impact factor 4)
122. Benhamou PY, Milliat-Guittard L, Wojtusciszyn A, Kessler L, Toso C, Baertschiger R , Debaty I, Badet L, Penfornis A, Thivolet C, Renard E, Bayle F, Morel P, Morelon E, Colin C, Berney T on behalf of the GRAGIL. *Quality of life after islet transplantation: data from the GRAGIL 1 & 2 trials.* Diabetic Medicine 2009;26(6):617-21 (Impact factor 2.9)
123. Wojtusciszyn A., Andres A., Morel P., Charvier S., Armanet M., Toso C., Choi Y., Bosco D. and Berney T. *Immunomodulation by blockade of the TRANCE co-stimulatory pathway in murine allogeneic islet transplantation.* Transplant Int 2009; 22: 931-939 (Impact factor 3.3)
124. Emamaullee J., Toso C., Merani S., Shapiro A.M.J. *Costimulatory blockade with belatacept in clinical and experimental transplantation – a review.* Expert Opinion On Biological Therapy 2009;9(6):789-96 (Impact factor 3.2)
125. Toso C., Kneteman N.M., Shapiro A.M.J., Bigam D.L. *The estimated number of patients with hepatocellular carcinoma selected for liver transplantation using expanded selection criteria.* Transplant Int 2009; 22: 869-875 (Impact factor 3.3)
126. Merani S., Edgar R.L., Toso C., Emamaullee J., Thiesen A., Shapiro A.M.J. *AEB-071 has minimal impact on onset of autoimmune diabetes in NOD mice* Autimmunity 2009 Mar;42(3):242-8 (Impact factor 2.8)
127. Emamaullee JA, Davis J, Merani S, Toso C, Elliott JF, Thiesen A, and Shapiro AMJ *Inhibition of Th17 cells regulates autoimmune diabetes in NOD mice.* Diabetes 2009 Jun;58(6):1302-11 (Impact factor 8.5)
128. Toso C., Asthana S., Bigam D., Shapiro J., Kneteman N. *Re-assessing selection criteria prior to liver transplantation for hepatocellular carcinoma using the SRTR database.* Hepatology 2009; 49(3): 832-838 (Impact factor 10.8)
Editorial: Sanchez W. Expanding Transplant Criteria for Hepatocellular Carcinoma: Small Steps Down a Long Road. Hepatology 2009; 49(3): 724-725
129. Merani S., Pawlick R., Edgar R., Toso C., Emamaullee J., Anderson C.C., Shapiro A.M.J. *Protein Kinase C inhibitor, AEB-071, acts complementarily with cyclosporine to prevent islet rejection in rats.* Transplantation 2009; 87(1): 59-65 (Impact factor 3.5)

130. Emamaullee J.A., Merani S., Toso C. Kin T., Al-Saif F., Truong W., Pawlick R., Davis J., Edgar R., Lock J., Bonner-Weir S., Knudsen L.B., and Shapiro A.M.J. *Porcine marginal mass islet autografts resist metabolic failure over time and are enhanced by early treatment with liraglutide.* Endocrinology 2009; 150(5): 2145-52. (Impact factor 4.8)
131. Toso C., Serre-Beinier V., Emamaullee J., Merani S., Armanet M., Wojtusciszyn A., Bosco D., Calandra T., Roger T., Morel P., Shapiro A.M.J. and Berney T. *The role of macrophage migration inhibitory factor in mouse islet transplantation.* Transplantation 2008;86(10):1361-1369. (Impact factor 3.8)
132. Merani S., Toso C., Emamaullee J., Shapiro A.M.J. *Defining an optimal surgical implantation site for clinical islet transplant.* British J Surgery 2008; 95(12): 1449-1461. (Impact factor 4.9)
133. Toso C., Edgar R., Pawlick R., Emamaullee J., Merani S., Parastoo D., Mueller T.F., Shapiro A.M.J. *Effect of different induction strategies on effector, regulatory and memory lymphocyte sub-populations in clinical islet transplantation.* Transplant Int 2009; 22:182-191 (Impact factor 3.1)
134. Toso C., Trotter J., Wei A., Bigam D., Shah S., Lancaster J., Grant D., Greig P., Shapiro J., Kneteman N. *Total Tumor Volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma.* Liver Transplantation 2008; 14: 1107-1115 (Impact factor 4.1)
Editorial: Roayaie S., Schwartz M. Expansion of criteria for transplanting patients with hepatocellular carcinoma. Liver Transplant 14: 1071-1072
135. Merani S., Truong W., Emamaullee J.A., Toso C., Knudsen L.B., Shapiro A.M. *Liraglutide, a long-acting human glucagon-like peptide 1 analogue, improves glucose homeostasis in marginal mass islet transplantation in mice.* Endocrinology. 2008; 149(9): 4322-4328 (Impact factor 4.9)
136. Emamaullee J, Davis J, Pawlick R, Toso C, Merani S, Cai S, Tseng B, and Shapiro J. *The caspase selective inhibitor EP1013 augments human islet graft function and longevity in marginal mass islet transplantation in mice.* Diabetes 2008; 57: 1556-1566 (Impact factor 8.4)
137. Toso C., Vallee JP, Morel P, Ris F, Demuylder-Mischler S, Lepetit-Coiffe M, Marangon N, Saudek F, Shapiro J, Bosco D, Berney T *Clinical Magnetic Resonance Imaging of Pancreatic Islet Grafts after Iron Nanoparticle Labelling.* Am J Transplantation 2008; 8: 701-706 (Impact factor 6.6)
138. Toso C., Shapiro AMJ, Bowker S., Dinyari P., Paty B., Ryan EA., Senior P., Johsson JA. *Quality of life after islet transplant: impact of the number of islet infusions and of the metabolic outcome.* Transplantation 2007; 84: 664-666 (Impact factor: 4)
139. Toso C., Al-Qahtani M., Alsaif FA., Bigam DL., Meeberg G., Shapiro AMJ., Bain VG., Kneteman NM *ABO-incompatible liver transplantation for critically ill adult patients.* Transplant International 2007; 20: 675-682 (Impact factor: 2.3)
140. Toso C., Meeberg, AG., Bigam DL., Oberholzer J., Shapiro AMJ., Gutfreund K., Ma MM., Mason AL., Wong WWS., Bain VG., Kneteman NM. *De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side-effects.*

- Transplantation 2007; 83: 1162-1168 (Impact factor: 3.6)
141. Toso C., Zaidi H., Morel P., Armanet M., Wojtuszczyz A., Mai G., Baertschiger R., Buhler L., Berney T. *Assessment of 18F-FDG-leucocyte imaging to monitor rejection after pancreatic islet transplantation.*
Transplant Proc 2006; 38: 3033-3034 (Impact Factor: 1)
 142. Berney T., Mamin A., Shapiro AMJ., Ritz-Laser B., Bruhlart MC., Toso C., Demuylder-Mischler S., Armanet M., Baertschiger R., Wojtuszczyz A., Benhamou PY., Bosco D., Morel P., Philippe J. *Detection of insulin mRNA in the peripheral blood after human islet transplantation predicts deterioration of metabolic control.*
American Journal of Transplantation 2006; 6: 1704-11 (Impact Factor: 6.8)
 143. Toso C., Baertschiger R., Morel P., Bosco D., Armanet M., Wojtuszczyz A., Badet L., Philippe J., Becker C., Hadaya K., Majno P., Bühler L., Berney T. and the GRAGIL group *Sequential kidney/islet transplantation: Efficacy and safety assessment of a steroid-free immunosuppression protocol.*
American Journal of Transplantation 2006; 6: 1049-58 (Impact Factor: 6.8)
 144. Sigrist S., Ebel N., Langlois A., Bosco D., Toso C., Kleiss C., Mandes K., Berney T., Pinget M., Belcourt A., Kessler L. *Role of chemokine signaling pathways in pancreatic islet rejection during allo- and xenotransplantation.*
Transplant Proc 2005; 37: 3516-8 (Impact Factor: 0.8)
 145. Wojtuszczyz A., Bosco D., Morel P., Baertschiger R., Armanet M., Kempf MC., Badet L., Toso C., Berney T. *A comparison of cold storage solutions for pancreas preservation prior to islet isolation.*
Transplant Proc 2005; 37: 3396-7 (Impact Factor: 0.8)
 146. Toso C., Majno P., Andres A., Rubbia-Brandt L., Berney T., Buhler L., Morel P., Mentha G. *Management of hepatocellular adenoma: solitary-uncomplicated, multiple and ruptured tumors.*
W. J. Gastroenterol 2005; 11(36): 5691-95 (Impact Factor: 3.3)
 147. Andres A., Toso C., Morel P., Demuylder-Mischler S., Bosco D., Baertschiger R., Pernin N., Bucher P., Majno PE., Buhler LH., Berney T. *Impairment of renal function after islet transplant alone or islet-after-kidney transplantation using a sirolimus/tacrolimus-based immunosuppression regimen.*
Transplant Int 2005; 18 (11): 1226-30 (Impact Factor: 1.8)
 148. Mai G., Huy NT.; Morel P., Mei J., Andres A., Bosco D., Baertschiger R., Toso C., Berney T., Majno P., Mentha G., Trono D., Buhler LH. *Treatment of fulminant liver failure by transplantation of microencapsulated primary or immortalized xenogeneic hepatocytes.*
Xenotransplantation 2005; 12: 457-64 (Impact Factor: 2.1)
 149. Bosco D., Meda P., Morel P., Matthey-Doret D., Toso C., Buhler L.H., Berney T. *Expression and secretion of alpha 1- proteinase inhibitor are regulated by proinflammatory cytokines in human pancreatic islet cells.*
Diabetologia 2005; 48: 1523-33 (Impact Factor: 5.3)
 150. Berney T., Malaise J., Morel P., Toso C., Demuylder-Mischler S., Majno P., Buhler L., Mentha G. *Impact of HLA matching on the outcome of simultaneous pancreas-kidney transplantation.*
Tranplant Proc 2005 ; 37 : 2846-7 (Impact Factor : 0.8)

151. Andres A., Bosco D., Morel P., Toso C., Baertschiger R., Buhler L., Berney T. *Islet transplantation in a recipient presenting the factor V Leiden mutation.*
Transplantation 2005; 79(12): 1771-2 (Impact Factor: 3.6)
152. Toso C., Mathe Z., Morel P., Oberholzer J., Bosco D., Sainz-Vidal D., Hunkeler D., Buhler L., Wandrey C., Berney T. *Effect of microcapsule composition and short term immunosuppression on intraportal biocompatibility.*
Cell Transplantation 2005; 14(2-3): 159-67 (Impact Factor: 3.5)
153. Kempf MC., Andres A., Morel P., Benhamou PY., Bayle F., Kessler L., Badet L., Thivolet C., Penformis A., Renoult E., Brun JM., Atlan C., Renard E., Collin C., Milliat-Guittard L., Pernin N., Demuylder-Mischler S., Toso C., Bosco D., Berney T *Logistics and transplant coordination activity in the GRAGIL swiss-french multicenter network of islet transplantation.*
Transplantation 2005 ; 79(9) : 1200-5 (Impact Factor 3.9)
154. Andres A., Toso C., Morel P., Demuylder-Mischler S., Bosco D., Bartschiger R., Pernin N., Bucher P., Majno P., Buhler L., Berney T. *Impact of a sirolimus/tacrolimus-based immunosuppressive regimen on kidney function after islet transplantation.*
Transplant Proc 2005 ; 37(2) : 1326-7 (Impact factor :0.8)
155. Bucher P., Oberholzer J., Bosco D., Mathe Z., Toso C., Buhler L., Berney T., Morel P. *Microbial surveillance during human pancreatic islet isolation.*
Transpl Int 2005 ; 18(5) : 584-9 (Impact Factor : 1.8)
156. Toso C., Andres A. (both first authors contributed equally to the work), Morel P., Bosco D., Bucher P., Oberholzer J., Mathe Z., Mai G., Wekerle T., Berney T., Buhler L. *Macrophage depletion prolongs discordant but not concordant islet xenograft survival.*
Transplantation 2005;79(5) : 543-9 (Impact Factor: 3.9)
157. Toso C., Zaidi H., Morel P., Armanet M., Andres A., Pernin N., Baertschiger R., Slosman D., Buhler L, Bosco D, Berney T. *Positron-emission tomography imaging of early events after transplantation of islets of Langerhans.*
Transplantation 2005; 79(3): 353-5 (Impact Factor: 3.9)
158. Toso C., Erne M., Lenzlinger P., Schmid JF., Buchel H., Melcher G., Morel P. *Intussusception as cause of bowel obstruction in adults.*
Swiss Med Weekly 2005 ; 135 : 87-90 (Impact Factor : 1.2)
159. Berney T., Malaise J., Morel P., Toso C., Demuylder-Mischler S., Majno P., Buhler L., Mentha G. *Impact of HLA matching on the outcome of simultaneous pancreas-kidney transplantation.*
Nephrol Dial Transplant 2005 ; 20 : ii48-ii53 (Impact Factor : 3)
160. Andres A., Toso C., Morel P., Bosco D., Bucher P., Oberholzer J., Mathe Z., Mai G., Wekerle T., Berney T., Buhler L. *Phylogenetic disparity influences the predominance of direct over indirect pathway of antigen presentation in islet xenotransplantation.*
Transplant Proc 2005 ; 37(1) : 463-5 (Impact Factor : 0.8)
161. Berney T., Bucher P., Mathe Z., Andres A., Bosco D., Mage R., Toso C., Oberholzer J., Becker C., Philippe J., Buhler L., Morel P. *Islet of Langerhans allogeneic transplantation at the university of Geneva in the steroid free era in islet after kidney and simultaneous islet-kidney transplantations.*
Transplant Proc 2004;36(4):1121-2 (IF : 0.5)

162. Bucher P., Mathe Z., Bosco D., Oberholzer J., Toso C., Andres A., Buhler L., Morel P., Berney. *Microbial surveillance during human pancreatic islet isolation.*
Transplant Proc 2004;36(4):1147-8 (IF : 0.5)
163. Mathe Z., Bucher P., Bosco D., Andres A., Fux C., Toso C., Oberholzer J., Wandrey C., Sainz D., Espinosa D., Buhler L., Morel P., Berney T. *Fibrotic Infiltration around intraportally injected Barium-alginate microbeads can be reduced by short course immunosuppression.*
Transplant Proc. 2004;36(4):1199-200 (IF : 0.5)
164. Ris F., Toso C., Unno Veith F., Majno P., Morel P., Oberholzer J. *Are criteria for islet and pancreas donor sufficiently different to minimize competition?*
Am J Transplantation 2004;4:763-6 (IF : 5.3)
165. Sigrist S., Oberholzer J., Bohbot A., Esposito G., Mandes K., Lamartine P., Toso C., Bucher P., Berney T., Belcourt A., Pinget M., Kessler L. *Activation of human macrophages by allogeneic islet preparations: Inhibition by AOP-Rantes and heparinoids.*
Immunology 2004 Apr;111(4):416-21 (IF : 3)
166. Toso C., Morel Ph., Shapiro J., Bucher P., Mathe Z., Demeuylder S., Bosco D., Berney T., Philippe J. and Oberholzer J. *Insulin-independence after conversion to tacrolimus and sirolimus based immunosuppression in islet-kidney recipients.*
Transplantation 2003 May;3(5):631-3 (IF : 3.6)
167. Asmis L., Hadaya K., Majno P., Toso C., Triponez F., Starobinski M. *Acquired and reversible Pelger-Huët anomaly (PHA) of polymorphonuclear neutrophils in three transplant patients receiving mycophenolate mofetil (MMF) therapy.*
Eur. J. Hematology 2003 Oct;76(7):1133-4 (IF : 1.7)
168. Toso C., Berney T., Oberholzer J., Chave JP., Martin PY., Zeender E., Bosco D., Morel P. *Kidney-pancreas transplantation in a long-term non-progressor HIV-infected recipient.*
American Journal Transplant 2003; 3: 631-3 (IF: 5.7)
169. Toso C., Oberholzer J., Ceausoglu I., Ris F., Rochat B., Rehor A., Bucher P., Wandrey C., Schuldt U., Lou J., Morel Ph., Hunkeler D. *Intraportal injections of 400µm multicomponent microcapsules in a large animal model.*
Transplantation Int. 2003 Jun;16(6):405-10 (IF : 1.2)
170. Toso C., Rubbia-Brandt L., Negro F., Morel P., Mentha G. *Hepatocellular adenoma and Stein-Leventhal syndrome.*
Liver Int 2003 Feb;23(1):35-7 (IF : 2.1)
171. Kessler L., Passemard R., Benhamou PY., Oberholzer J., Bucher P., Toso C., Meyer L., Penformis F., Badet L., Wolf P., Morel Ph. *Reduction of blood glucose variability by islet transplantation: interest of continuous glucose monitoring.*
Diabetes Care 2002 Dec;25(12):2256-62 (IF : 5.5)
172. Toso C., Ris F., Mentha G., Oberholzer J., Morel Ph and Majno P. *Potential impact of liver splitting on the number of available grafts.*
Transplantation 2002 Jul; 74(2): 156-7
Comments: Potential impact of liver splitting on the number of available grafts.
Transplantation 2002; 74: 222. Farges O. (IF : 3.3)

173. Yang H., Majno P., Morel P., Toso C., Triponez F., Oberholzer J., Mentha G., Lou J. *Prostaglandin e(1) protects human liver sinusoidal endothelial cell from apoptosis induced by hypoxia reoxygenation.*
Microvasc Res 2002 Jul;64(1):94-103 (IF : 1.5)
174. Maedler K., Fontana A., Ris F., Sergeev P., Toso C., Oberholzer J., Lehmann R., Bachmann F., Tasinato A., Spinass G., Halban P, and Donath M *FLIP switches Fas-mediated glucose signaling in human pancreatic β -cells from apoptosis to cell replication.*
Proc Natl Acad Sci USA 2002 Jun 11; 99(12):8236-8241 (IF : 10.7)
175. Ritz-Laser B., Oberholzer J., Toso C., Brulhart M.-C., Zakrewska K., Ris F., Bucher P., Morel Ph. *Molecular detection of circulating beta-cells after islet transplantation.*
Diabetes 2002 Mar; 51:557-61 (IF : 8.3)
176. Triponez F., Oberholzer J., Toso C., Majno P., Martin P.Y. and Morel Ph. *Human islet re-transplantation in a patient with type I diabetes.*
Transplant Int 2002 Apr; 15(4):200-2 (IF : 2.5)
177. Toso C., Oberholzer J., Ris F., Triponez F., Bucher P., Demirag A., Anderegg E., Buhler L., Cretin N., Fournier B., Majno P., Hong Y., Lou J., Morel P. *Factors affecting human islet of Langerhans isolation yields.*
Transplantation Proceedings 2002 May;34(3):823-5 (IF : 0.5)
178. Oberholzer J., Toso C., Triponez F., Ris F., Bucher P., Demirag A., Lou J., Majno P., Buhler L., Philippe J., Morel Ph. *Human islet allotransplantation with basiliximab in type I diabetic patients with end-stage renal failure.*
Transplantation Proceedings 2002 May;34(3):823-5 (IF : 0.5)
179. Majno P., Mentha G., Morel P., Le Coultre C., Oberholzer J., Toso C., Borisch B., Fasel J. *Left lobe splitting and full right-full left splitting: study of the portal anatomy on corrosion casts and on autopsy livers.*
Transplantation Proceedings 2002 May;34(3):769-70 (IF : 0.5)
180. Benhamou P.Y., Oberholzer J., Toso C., Kessler L., Penfornis A., Bayle F., Thivolet C., Martin X., Lefrançois N., Badet L., Colin C., Morel Ph. *Human islet transplantation network for type 1 diabetes: First (1999-2000) data from the swiss-french GRAGIL consortium.*
Diabetologia 2001 Jul;44(7):859-64 (IF : 6.3)
181. Triponez F., Oberholzer J., Morel Ph., Toso C., Yu D., Cretin N., Bühler L., Majno P., Mentha G., Lou J. *Xenogeneic islet re-transplantation in mice triggers an accelerated, species-specific rejection.*
Immunology 2000 Dec;101(4):548-554 (IF : 2.7)
182. Toso C., Brandhorst D., Triponez F., Bühler L., Morel Ph., Oberholzer J. *Isolation of adult porcine islets of Langerhans*
Cell transplantation 2000 May-Jun;9(3):297-305 (IF : 2.2)
183. Toso C., Robert J., Pugin F., Berney T., Spiliopoulos A. *Thoracic outlet syndrome: influence of personal history and surgical technique on long-term results.*
Eur J Cardiothorac Surg. 1999 Jul;16(1):44-7 (IF : 1.5)

Review articles in peer-reviewed journals

1. Oldani G., Peloso A., Lacotte S., Meier R., Toso C. *Xenogeneic chimera - generated by blastocyst complementation - as a potential unlimited source of recipient-tailored organs* Xenotransplantation 2017; in press (Impact factor 4)
2. McLin V.A., Allen U., Boyer O., Bucuvalas J., Colledan M., Cuturi M.C., d'Antiga L., Debray D., Dezsofi A., de Ville de Goyet J., Dhawan A., Durmaz O., Falk C, Feng S., Fischler B, Franchi-Abella S., Frauca E., Ganschow R., Gottschalk S., Hadzic N., Hierro L., Horslen S., Hubscher S., Karam V., Kelly D., Maecker-Kolhoff B., Mazariegos G., McKiernan P., Melk A., Ng V., Nobili V., Ozgenç F., Reding R., Sciveres M., Sharif K., Socha P., Toso C., Vajro P., Verma A., Wildhaber B., Baumann U. *Early and late factors impacting outcomes in pediatric liver transplantation: summary of an ESPGHAN Conference* JPGN 2017; in press (Impact factor 2.4)
3. Delaune V., Berney T., Lacotte S., Toso C. *Intraportal islet transplantation: the impact of the liver micro-environment* Transplant Int 2017; 30(3): 227-238 (Impact factor 2.8)
4. Torzilli G., Adam R., Viganò L., Imai K., Goransky J., Fontana A., Toso C., Majno P., de Santibañes E. *Surgery of Colorectal Liver Metastases: Pushing the Limits* Liver Cancer 2017; 6(1): 80-89
5. Andres A., Majno P., Terraz S., Morel P., Roth A., Rubbia-Brandt L., Schiffer E., Ris F., Toso C. *Management of patients with colorectal liver metastasis in eleven questions/answers* Expert Rev Anticancer 2016; 16(12): 1277-1290 (Impact factor 2.1)
6. Duvoux C., Toso C. *mTOR inhibitor therapy: Does it prevent HCC recurrence after liver transplantation?* Transplantation reviews 2015; 29(3): 168-174 (Impact factor 3.8)
7. Orci L.A., Meyer J., Combescure C., Buhler L., Berney T., Morel P., Toso C. *A meta-analysis of extended versus standard lymphadenectomy in patients undergoing pancreatoduodenectomy for pancreatic adenocarcinoma* HPB 2015; 17(7): 565-72 (Impact factor 2.7)
8. Toso C., Mazzaferro V., Bruix J., Freeman R., Mentha G., Majno P. *Towards a better liver graft allocation that accounts for candidates with and without hepatocellular carcinoma* Am J Transplant 2014; 14(10): 2221-2227 (Impact factor 5.7)
9. Orci L.A., Lacotte S., Oldani G., Morel P., Mentha G., Toso C. *The role of hepatic ischaemia-reperfusion injury and liver parenchymal quality on cancer recurrence* Dig Dis Sci 2014; 59(9): 2058-2068 (Impact factor 2.6)
10. Orci L.A., Meier R.P.H, Morel P., Staszewicz W., Toso C. *Systematic review and meta-analysis of percutaneous subclavian vein puncture versus surgical venous cutdown for the insertion of a totally implantable venous access device* British J Surg 2014; 101(2):8-16 (Impact factor 5.5)
11. Buchs N.C., Oldani G., Orci L.A., Majno P.E., Mentha G., Morel P., Toso C. *Current status of robotic liver resection: a systematic review*

- Expert Rev Anticancer Ther 2014; 14(2): 237-246 (Impact factor 2.2)
12. Mentha G., Terraz S., Andres A., Toso C., Rubbia-Brandt L., Majno P. *Operative management of colorectal liver metastases*
Seminars in Liver Disease 2013; 33(3):262-272 (Impact factor 8.3)
 13. Orci L., Oldani G., Andres A., Mentha G., Morel P., Toso C. *Systematic review and meta-analysis of fibrin sealants for patients undergoing pancreas resection*
HPB 2013, In press (Impact factor 1.9)
 14. Orci L., Toso C., Mentha G., Morel P., Majno P. *Systematic review and meta-analysis of the effect of perioperative steroids on ischaemia-reperfusion injury and surgical stress response in patients undergoing liver resection*
British J Surg 2013; 100(5): 600-609 (Impact factor 4.8)
 15. Rougemont-Pidoux A.L., Mc Lin V., Toso C., Wildhaber B. *Adult hepatoblastoma: learning from children*
J. of Hepatology 2012; 56(6): 1392-403 (Impact factor 9.9)
 16. Borot S., Crowe L.A., Toso C., Vallee J.-P., Berney T. *Non-invasive techniques in islet transplantation.*
Curr Diabetes Rep 2011; 11(5): 375-383 (Impact factor 2.5)
 17. Germani G., Gurusamy K., Garcovich M., Toso C., Fede G., Hemming A., Suh K.S., Weber A., Burroughs A.K. *What matters: Number of tumours, size of largest tumour, or total volume of tumour?*
Liver Transpl. 2011; 17: S58-S66 (Impact factor 3.4)
 18. McCall M., Merani S., Toso C., Shapiro A.M.J. *Sotrotaurin (AEB-071).*
Drugs of the future 2009;34(8) (Impact factor 0.5)
 19. Kneteman NM and Toso C. *In vivo study of HCV in mice with chimeric human liver.*
Methods Mol Biol. 2009; 510: 383-99.
 20. Toso C., Emamaullee J., Merani S., Shapiro J. *The role of Macrophage Migration Inhibitory Factor on glucose metabolism and diabetes.*
Diabetologia 2008; 51(11): 1937-46. (Impact factor 6.4)
 21. Ris F., Toso C., Morel P., Lepetit-Coiffe M., Vallee JP., Berney T. *Imaging of islet grafts*
Current Opinion in Organ Transplantation 2007;12: 659-663 (Impact factor: 0.5)
 22. Kneteman N., Toso C. *Book review: Atlas of organ transplantation* by A. Humar, AJ Matas, WD Payne.
American Journal of Transplantation 2007; 7: 1680 (Impact Factor: 6.4)
 23. Berney T., Toso C. *Monitoring of islet grafts.*
Diabetes Metabolism 2006; 32: 503-512 (Impact Factor: 1.7)
 24. Majno P., Mentha G., Terraz S., Rubbia Brandt L., Berney T., Buhler L., Toso C., Huber O., Spahr L., Morard I., Hadengue A., Becker C., Terrier F., Morel P. *Treatment of hepatocellular carcinoma at the dawn of the third millenium: liver transplantation and its alternatives.*
Acta Chir Belg 2004 ;67(2) :206-22 (IF : 0.3)

25. Berney T., Buhler L., Caulfield A., Oberholzer J., Toso C., Alejandro R., Cooper D.K.C., Ricordi C., Morel Ph. *Transplantation of islet of Langerhans: new developments.*
Swiss Med Wkly 2001 Dec; 131:671-80 (IF : 0.8)
26. Berney T., Caulfield A., Oberholzer J., Buhler L., Toso C., Morel Ph. *Islet of Langerhans autotransplantation: rationale, results and new developments.*
Graft 2001 Dec;4(8):535-43
27. Oberholzer J., Toso C., Ris F., Bucher P., Triponez F., Demirag A., Lou J., Morel P.
Beta cell replacement for the treatment of diabetes.
Ann N Y Acad Sci 2001 Nov;944:373-87 (IF : 1.6)

Editorials in peer-reviewed journals

1. Iranmanesh P., Toso C. *Reply to the Letter to the Editor by Qi et al. entitled "Insufficient accuracy of computed tomography-based portal pressure assessment in hepatitis B virus-related cirrhosis"*.
J. Hepatol 2017 (Impact factor 12.5)
2. Berney T., Andres A., Toso C., Majno P., Squifflet J.P. *mTOR Inhibition & Clinical Transplantation: Pancreas & Islet*
Transplantation 2017 (Impact factor 3.7)
3. Andres A., Assalino M., Oldani G., Toso C., Berney T. *Procurement professionalization: a mandatory step to improve the availability and quality of whole pancreas grafts*
Transplant Int 2016;30(2):115-116 (impact factor 2.9)
4. Toso C., Andres A., Hernandez-Alejandro R., Kneteman N., Majno P. *AFP: further evidence to add a biological marker to refine Milan criteria*
Liver Int 2016; 36(11): 1580-1581 (Impact factor 4.9)
5. Toso C., Mentha G., Majno P. *Integrating sorafenib into an algorithm for the management of post-transplant hepatocellular carcinoma recurrence*
J. Hepatol 2013; 59(1): 3-5. (Impact factor 9.9)
6. Toso C., Kneteman N. *Does mycophenolate mofetil reduce the risk of late acute rejection after liver transplantation?*
Nature Clin Pract Gastroenterol Hepatol 2006; 3: 664-665 (Impact Factor: 2.6)

Articles in non peer-reviewed journals

- 1 Jung M., Hagen M.E., Iranmanesh P., Majno P., Buhler L.H., Toso C., Cornateanu S., Buchs N., Morel P. *Robotic-assisted liver surgery*
Rev Med Suisse 2015; 11: 1331-4
- 2 Kawahara T., Toso C., Furukawa H. *Recent Progress in Minimally Invasive Pancreas Surgery*
Jutendo Medical Journal 2015; 61: 126-130
- 3 Buchs C.N., Morel P., Toso C. *Robotic liver resection*
Jutendo Medical Journal 2015; 61: 121-125
- 4 Toso C., Mentha G and for the Hepato-Pancreatico-Biliary Centre team at the Geneva University Hospitals. *Collective intelligence for a more efficient patient management*
SwissKnife 2014 ; 3 :18-19
- 5 Meier R.P.H., Berney T., Morel P., Toso C., Muller Y.D. *Transplantation d'îlots de Langerhans: avancées récentes et perspectives d'avenir*
SwissKnife 2014 ; 1 : 14-15
- 6 Toso C. *Congrès de la Société Suisse de Chirurgie 2012: science, médecine de pointe, écologie et humanisme.*
SwissKnife 2012; 3 : 4
- 7 Holzer T., Poletti P.A., Vlastos G., Berney T., Majno P., Mentha G., Morel P., Toso C. *Investigation et traitement des pathologies digestives chirurgicales pendant la grossesse.*
SwissKnife 2011; 2 : 16-17
- 8 Mentha G., Majno P., Morard I., Toso C., Antonino-Madrid A., Berney T., Morel P., Rubbia-Brandt L., Terraz S., Moradpour D., Hadengue A., Giostra G. *La transplantation hépatique.*
Revue Médicale Suisse 2011; 7(279): 192-193
- 9 Andres A., Majno P., Morel P., Toso C., Gervaz P., Terraz S., Rubbia-Brandt L., Roth A., Mentha G. *Le traitement inversé du cancer colorectal avec métastases hépatiques synchrones.*
SwissKnife 2010 ; 3 : 12-13
- 10 Gonzalez M., Toso C., Zufferey G., Roiron T., Majno P., Mentha G., Morel Ph. *Quand faut-il réaliser une cholécystectomie? Une décision pas toujours simple.*
Revue Médicale Suisse 2006 June; 2(70): 1586-92
- 11 Andres A., Majno P., Toso C., Rubbia-Brandt L., Berney T., Buhler L. H., Huber O., Morel Ph., Mentha G. *Quand référer un patient pour une résection hépatique?*
Médecine et Hygiène 2004 June 16; 62: 1335-41
- 12 Berney T., Mathe Z., Bucher P., Andres A., Bosco D., Toso C., Buhler L., Morel P. *Autotransplantation d'îlots de Langerhans pour la prévention du diabète après résection pancréatique étendue.*
Médecine et Hygiène 2003 June 18; 60: 1205-13
- 13 Toso C., Mathe Z., Oberholzer J. *Current status of islet transplantation in Europe.*

Insulin-Free Times, Spring/Summer 2001

- 14 Oberholzer J., Toso C., Benhamou P.Y., Becker C., Philippe J., Morel Ph. *La transplantation d'îlots de Langerhans pour le traitement du diabète.* Bulletin des médecins suisses 2001 Feb; 82(8):390-400
- 15 Toso C., Oberholzer J., Ris F., Becker Ch., Philippe J., Morel Ph. *Le traitement du diabète par transplantation : quelles sont les indications ?* Médecine et Hygiène 2000 Nov. 8 ;58 : 2218-22

Book chapters

- 1 L. A. Orci, C. Toso. *Notion d'auteur*. In Médecine et Hygiène eds. Fiches d'épidémiologie. In press 2016
- 2 C. Toso. *Qu'est-ce qu'un facteur d'impact (impact factor) ?* In Médecine et Hygiène eds. Fiches d'épidémiologie. In press 2016
- 3 L. A. Orci, C. Toso. *Peer-review*. In Médecine et Hygiène eds. Fiches d'épidémiologie. In press 2016
- 4 C. Toso, L. A. Orci. *Etude cas-témoin*. In Médecine et Hygiène eds. Fiches d'épidémiologie. In press 2016
- 5 C. Toso, L. A. Orci. *Etude de cohorte*. In Médecine et Hygiène eds. Fiches d'épidémiologie. In press 2016
- 6 L. A. Orci, C. Toso. *Les études transversales*. In Médecine et Hygiène eds. Fiches d'épidémiologie. In press 2016
- 7 L. A. Orci, C. Toso. *Comment limiter la confusion?* In Médecine et Hygiène eds. Fiches d'épidémiologie. In press 2016
- 8 L. A. Orci, C. Toso. *Facteurs de confusion*. In Médecine et Hygiène eds. Fiches d'épidémiologie. In press 2016
- 9 L. A. Orci, C. Toso. *Erreur de mesure*. In Médecine et Hygiène eds. Fiches d'épidémiologie. In press 2016
- 10 L. A. Orci, C. Toso. *Causalité*. In Médecine et Hygiène eds. Fiches d'épidémiologie. In press 2016
- 11 L. A. Orci, C. Toso. *Biais*. In Médecine et Hygiène eds. Fiches d'épidémiologie. In press 2016
- 12 Buchs N.C., Ris F., Toso C. *Liver or rectum first?* In John Wiley eds. *Colorectal Surgery: Clinical care and management*. 2016: 56-58
- 13 Manuel O., Toso C., Pascual M. *Kidney and pancreas transplant recipients*. In Opal, Calandra eds. *Infectious Diseases 4^e*. 2015
- 14 Toso C., Shapiro AMJ. *Islet transplantation for the treatment of type I diabetes*. In Walker and Jara, eds. *The Handbook of systemic autoimmune disease: Endocrine Volume*. 2008; 9: 271-288
- 15 Toso C., Mason A., Kneteman N. *Novel approaches to immunosuppression in liver transplantation*. In Gregory, Everson, and Trotter eds. *Liver Transplantation: Challenging Controversies and Topics*. Humana Press, 2008; 7
- 16 Toso C., Berney T. *Islet graft monitoring and imaging*. In Shapiro and Shaw, eds. *Islet transplantation and beta cell replacement therapy*. New-York. 2007: 179-191

Theses

Privat Docent Thesis:

“Liver transplantation for the treatment of hepatocellular carcinoma” (2010)
University of Geneva, Switzerland

PhD Thesis:

“Monitoring and improving islet transplant outcomes” (2009)
Supervisor: Prof. James Shapiro, University of Alberta, Edmonton, Canada

MD Thesis:

“Isolation, preservation and transplantation of pig islet of Langerhans: review and future perspectives” (1997)
Supervisor: Prof. Philippe Morel, University of Geneva, Switzerland

Invited presentations

- 1 Colloque du Nord-Vaudois. *Prise en charge chirurgicale des métastases hépatiques du cancer colorectal*. Yverdon, November 2017
- 2 6th Swiss HCC Day 2017. *Listing for transplantation patients with HCC*. Zurich, September 2017
- 3 Symposium “Current and future perspectives in primary liver tumors”. *Surgical treatment of hilar cholangiocarcinoma*. Rotterdam, September 2017
- 4 Porto Liver Meeting. *Hepatocellular carcinoma–Downstaging and bridge therapies*. Porto, June 2017
- 5 ILTS. *Liver transplantation for HCC: modelling the criteria*. Prague, May 2017
- 6 EA-HPBA. *Warm vs. cold split for OLT*. Mainz, May 2017
- 7 EASL- International Liver Congress. *Management of patient with hepatocellular carcinoma on the waiting list for liver transplantation*. Amsterdam April 2017
- 8 One Week Medical School, *Douleurs abdominales*. Geneva, March 2017
- 9 Journées medico-chirurgicales d’hépatologie et de gastro-entérologie 2016. *Le timing de la cholécystectomie après pancréatite et cholangite*, Geneva, Switzerland, November 2016
- 10 Lausanne Grandround, *Traitement chirurgical des patients avec métastases colorectales: new technologies and HPB surgery*. Lausanne, October 2016
- 11 EASL Hepatology School, *Liver nodules*. Geneva, September 2016
- 12 SASL School of Hepatology, *HCC resection*. Web-based, September 2016
- 13 Workshop on liver transplantation for colo-rectal metastases, *Why is transplantation for colo-rectal metastases a therapeutic option?* Porto Alegre, Brasil, April 2016
- 14 IHPBA 2016, *What is the ideal classification approach for organ allocation for HCC?* Sao Paolo, Brasil, April 2016
- 15 L Point Sharing Experiences, *Liver transplantation for cancer*, Vienna, March 2016
- 16 International Liver Transplantation Society meeting, *The Influence of Tumor Biology on Outcomes*. Chicago, USA, July 2015
- 17 ASRCC meeting, *Metastases hépatiques: indications, alternatives et strategies*. Lausanne, June 2015
- 18 Romanian HPB and transplant conference, *Liver transplantation for HCC*. Bucharest, Romania, March 2015
- 19 Colloque Astra, *Abcès et kystes hépatiques : prise en charge*. Geneva, March 2015

- 20 Journées medico-chirurgicales d'hépatologie et de gastro-entérologie 2014. *La mesure non-invasive de la pression portale*, Geneva, Switzerland, November 2014
- 21 Korean Society of Transplantation 2014 : *Ways to prevent recurrence after liver transplantation for HCC*, Seoul, October 2014
- 22 Association Française de Chirurgie 2014: Comment limiter le risque en chirurgie du foie ?, Paris, October 2014
- 23 EASL-ILC 2014, International Liver Congress: What do we need for personalized medicine in surgical procedures?, London, UK, April 2014
- 24 EASL-ILC 2014, International Liver Congress: Grand Round session on Liver tumours, London, UK, April 2014
- 25 European Society for the Study of Liver (EASL), Monothematic Conference on Liver Cancer. Surgery for HCC, Geneva, February 2014
- 26 Collège des Professeurs, Faculté de médecine, Université de Genève: Le traitement du cancer hépatocellulaire par transplantation, February 2014
- 27 Swiss Transplantation Society meeting 2014: Liver graft allocation between patients with and without hepatocellular carcinoma, Interlaken, January 2014
- 28 Bangalore HCC meeting 2014 : Management of HCC, current data, Bangalore, India, January 2014
- 29 Forum valaisan de gastro-entérologie. Kyste du pancréas : quand faut-il opérer ? Sion, Octobre 2013
- 30 Colloque omnipraticien de La Chaux-de-Fonds, Prise en charge des patients avec cancer colo-rectal et métastases hépatiques, La Chaux-de-Fonds, September 2013
- 31 ESPGHAM monothematic conference: Current paradigms and novel strategies in paediatric liver transplantation: mTOR inhibitor-based immunosuppression, Hannover, Germany, September 2013
- 32 Summer school of liver surgery and experimental practice, Prevention of post-transplant HCC recurrence, Pavia, Italy, June 2013
- 33 Transplant round. Liver transplantation for hepatocellular carcinoma, Toronto, May 2013
- 34 Interdisciplinary treatment of liver tumors. HCC: Downstaging to transplant, Essen, Germany, April 2013
- 35 Journées medico-chirurgicales d'hépatologie et de gastro-entérologie 2012. La transplantation du foie suite à l'introduction du MELD, Geneva, Switzerland, December 2012
- 36 Colloque hebdomadaire, Hôpital Henri Mondor. Le traitement du carcinome hépatocellulaire par transplantation, Paris, France, Avril 2012
- 37 Surgical and Gastroenterological Grand Rounds. Liver transplantation for the treatment of hepatocellular carcinoma, Zurich, Switzerland, February 2012

- 38 Journées medico-chirurgicales d'hépatologie et de gastro-entérologie 2011. Traitement du carcinome cholangio-cellulaire: comment faire la différence? Geneva, Switzerland, December 2011
- 39 Islet transplantation without borders. Islet transplantation in networks: the Swiss-French GRAGIL experience. Athen, Greece, December 2011
- 40 Oncology round. Reverse management of patients with colo-rectal cancer and advanced liver metastasis. Oxford, UK, August 2011
- 41 Liver round. Strategies to prevent recurrence after liver transplantation for hepatocellular carcinoma. Edmonton, Canada, July 2011
- 42 Bern Mini-Symposium Hepatology. Recurrence of hepatocellular carcinoma after liver transplantation. Bern, Switzerland, June 2011
- 43 Centre de transplantation d'organes meeting, Liver transplantation for hepatocellular carcinoma. Lausanne, March 2011
- 44 6th Annual Canadian Liver Transplant Forum. Waitlist criteria for HCC. Quebec City, Canada, February 2011
- 45 AIDPIT/EPITA Winter Symposium. GLP-1 therapy in islet transplantation. Igls, Austria, January 2011
- 46 Swiss Transplant Society meeting. Monitoring of islet and pancreas transplantation. Interlaken, January 2011
- 47 Journées medico-chirurgicales d'hépatologie et de gastro-entérologie 2010. Transplantation pour carcinome hépatocellulaire en 2010. Geneva, December 2010
- 48 Hepatocellular carcinoma meeting. How to prevent recurrence after transplantation for hepatocellular carcinoma? Bern, Switzerland, November 2010
- 49 Liver oncology meeting. Management of colorectal metastasis and hepatocellular carcinoma. Surat Oncology Center, Surat, Gujarat, India, November 2010
- 50 Satellite symposium to the ILTS 16th annual International congress: The art of surgery and medicine in liver transplantation: today and tomorrow. Downsizing as a selection tool in recipients with HCC for liver transplantation. Hong Kong, China, June 2010
- 51 World Kidney Day symposium. Transplantation rénale: où en sommes-nous en 2010? Geneva, March 2010
- 52 Colloque trans-départemental de transplantation. Transplantation hépatique pour carcinome hépato-cellulaire de grande taille et avec sirolimus. Geneva, March 2010
- 53 Colloque trans-départemental de transplantation. Comment améliorer le suivi après transplantation d'îlots pancréatiques? Etudes cliniques et pré-cliniques. Geneva, January 2010
- 54 Journées medico-chirurgicales d'hépatologie et de gastro-entérologie 2009, Carcinome cholangiocellulaire. Geneva, December 2009

- 55 International Pancreas and Islet Transplantation Association meeting. MRI imaging of grafted allogenic islets in transplant patients. Venice, Italy, October 2009
- 56 Alberta Transplant Institute. Liver transplantation for hepatocellular carcinoma using sirolimus and expanded recipient selection criteria. University of Alberta, AB, March 2009
- 57 Transplant Conference. Total Tumor Volume and alpha fetoprotein as predictors of outcome after liver transplantation for hepatocellular carcinoma. University of Minnesota, MN, January 2009
- 58 4th Annual Islet Workshop. Clinical magnetic resonance imaging of islet grafts using nanoparticle labeling. Newport Beach, CA, October 2008
- 59 Alberta Transplant Institute. Progress in post-transplant islet graft monitoring. University of Alberta, AB, January 2008
- 60 Innovations and standards. Pancreas transplant alone: is it a valuable option? Leipzig, Germany, October 2005
- 61 Congress of the Swiss Surgical Society. Port access complications: How to prevent them. Zurich, Switzerland June 2005.
- 62 4th International islet isolation workshop, Network of Islet Centers in Europe (NICE), Immunosuppression protocols and patient follow-up. Geneva, Switzerland May 2005.
- 63 Clinical meeting, Islet transplantation from bench to clinic. Sierre, Switzerland 2002.
- 64 French-Italian diabetology meeting, Islet isolation. Naples, Italy 2001.
- 65 Diabetology days, Islet transplantation update. Besançon, France 2001.